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Abstract
Background: Gram-negative resistance is a growing problem worldwide. It is generally
believed that rates of resistant bacteria within a hospital are a function of antibiotic use,
resistant organisms brought into the hospital, infection control efforts, and underlying
severity of patient illness. The relative contribution of each to a particular resistance
phenotype is unclear. P. aeruginosa is responsible for many hospital acquired infections
and it may become resistant to carbapenems. In addition, newer threats to the future
utility of the carbapenems are carbapenemase-producing K. pneumoniae
Purpose: To determine if there is an association between the volume and composition
of antibiotic use, geography, severity of illness and rates of carbapenem-resistant P.
aeruginosa and K. pneumoniae.
Methods: This is a retrospective ecological longitudinal investigation within the
University HealthSystem Consortium affiliated academic medical centers. Antibiotic use
data between January 1, 2006 and December 31, 2009 were obtained from billing
records and reported as days of therapy per 1000 patient days (DOT/1000 PD), in
addition to hospital characteristics (e.g. geographical location, bed size, case mix
index). “Whole house” antibiograms were obtained to determine rates and proportions
of carbapenem-resistant P. aeruginosa (CR-PA) and carbapenem resistant K.
pneumoniae (CR-KP). Also, CR-KP isolation was generated as a binary outcome.
Generalized estimating equations (GEE) were used to model CR-KP and CR-PA.
Results: CR-KP rates (1000PDs) increased from 0.07 in 2006 to 0.15 in 2009 (P=
0.0118) and CR-KP proportions increased from 1.3% in 2006 to 3.1% in 2009 (0.0003)

xi

within 40 hospitals over 2006-2009. However, CR-PA rates and proportions were stable
over the same period. Geographical location, carbapenems use, and antipseudomonal
penicillins use were significantly associated with CR-KP isolation. Thus, for every ten
DOT/1000 PDs increase in carbapenem use, the odds of CR-KP isolation increased by
42% (P=0.0149). In contrast, for every ten DOT/1000 PDs increase in antipseudomonal
penicillin use, the odds of CR-KP isolation decreased by 14%. However, there was no
significant model to explain CR-PA rates and proportions.
Conclusion: Carbapenems, antipseudomonal penicillins, and geographical location
were identified as risk factors associated with CR-KP isolation. These findings
emphasize the challenges associated with the treatment of multidrug- gram-negative
bacteria.
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CHAPTER 1
Introduction

1.1 Overview of the document
This dissertation describes a study designed to explain carbapenem resistant gramnegative bacteria in a consortium of academic medical health centers located across
the U.S. Antimicrobial drug use, severity of illness, and hospital demographics were
investigated as potential predictors of carbapenem-resistant P. aeruginosa (CR-PA) and
carbapenem resistant K. pneumoniae (CR-KP). This chapter provides background
information necessary to understand the significance of this project. The second chapter
reviews the available literature and provides more extensive background from previous
investigations; including epidemiology CR-PA and CR-KP, previously described risk
factors, and confounding factors. Chapter 3 describes the methodology used for the
dissertation project. The results are provided in Chapter 4, followed by a discussion and
concluding remarks in Chapter 5.
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1.2 Background

Multidrug-resistant gram negative bacteria
The antimicrobial drug resistance problem is increasing in the U.S. and worldwide. This
issue is getting more complicated because of two factors: emergence of multidrugresistance (MDR) gram-negative organisms; and the shortage of new, effective
treatment options against these resistant bacteria.[1-8] The current situation is
demanding new methods to improve antibiotic drug use in the clinical setting.
Antimicrobial Stewardship Programs (ASPs) are evolving all over the United States
hospitals; their mission is to improve the quality of antibiotic use, treatment outcomes,
and cost.[9- 12] This is valuable as antibiotic use at both the patient- and aggregatelevel has been shown to play a major role in bacterial resistance.[13-16] In addition, the
relationship between antibiotic use and bacterial resistance is further complicated by
patient risk factors and infection control measures which vary among health care
settings. [15, 17] The composition of patients within each hospital varies from one
hospital to another. Severely ill patients will presumably be at greater risk to develop
infections caused by resistant organisms; because they have impaired host defenses
and will receive more antibiotics compared to low risk patients.
Carbapenem antibiotics
Despite the increase in resistance rates against many beta-lactams, carbapenem
antibiotics still retain activity against most organisms and are considered the drug of
choice against extended-spectrum beta-lactams (ESBLs) producing
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Enterobacteriaceae, such as E. coli and K. pneumoniae. [18-20] Thus, developing
resistance against this class of antibiotics is considered a serious problem since the
remaining options, colistin or tigecycline, are more toxic and possibly less effective.[21]
Moreover, infections with carbapenem resistant gram-negative organisms are
associated with high rates of mortality and cost.[22-24]
Carbapenem-resistant gram negative bacteria
Carbapenem-resistant Klebsiella pneumoniae (CR-KP) is of special concern because of
its rapid spread, microbiological detection challenges, poor health outcomes, and it is
resistant to most antimicrobials.[25-29] Outbreaks of Klebsiella pneumoniae
carbapenamase (KPC)-producing Enterobacteriaceae have been reported in the U.S.
(with geographical variation) and all over the world. [30-35] According to the Centers for
Disease Control and Prevention (CDC), KPC has been reported in 35 states in the U.S.
in 2010 compared to one state in 2001.[36] In addition, carbapenem-resistant P.
aeruginosa (CR-PA) is often a multi-drug resistance bacteria that is associated with
significant health outcomes and difficult to be treated with complete eradication.[37,38]
Cofounding in Pharmacoepidemiology
Any epidemiologic investigation attempting to describe the relationship between an
exposure and an outcome must consider potential confounders. Confounding occurs
when a certain variable(s) influence the relationship between an exposure and
outcome.[39] The presence of confounding can result in overestimation of the
association of the true association, underestimation of the true association, or change in
the direction of the association.[40] Therefore, it is imperative to identify confounders
3

and control for them. In most situations, confounders are identified in advance based on
previous investigations or expert knowledge.[39,40] Severity of illness, hospital bed
size, and geographical location were identified as confounders.[15, 16, 41]
Multivariable modeling is one way to control for confounders at the level of statistical
analysis. [42]
Previous investigations
Prior antibiotic use (carbapenems, fluoroquinolones, and extended-spectrum
cephalosporins) and certain patient risk factors (e.g. ICU admission, mechanical
ventilation, length of hospitalization) were found to be independent risk factors
associated with CR-KP in several single centered case-control studies.[22,29,42-44]
These studies were of small sample size, not geographically distributed across the
nation which limit their generalizability. In addition, prior carbapenem use and other
patient factors (e.g. Foley catheters transfer from outside facility, mechanical ventilation)
were identified as independent risk factors associated with CR-PA in case-control
studies.[23,24,45,46] One multicenter study did not find an association between
carbapenem use and CR-PA in a model that is not adjusting for hospital
demographics.[47]
Preliminary results
The preliminary results reported trends in hospital antibacterial drug use in adult
patients from 22 US academic medical centers, all of which participated in UHC
programs. A significant finding was that broad-spectrum antibiotic use is increasing, in
part due to an overall increase in carbapenem use.[48] Also, using the same set of
hospitals they found that hospitals which restrict carbapenem antibiotic use (e.g.
4

imipenem, meropenem) actually use less carbapenem, and rates of CR-Pa are
significantly lower.[ 49]

1.3 Purpose
This study investigated carbapenem-resistance gram-negative bacteria: Pseudomonas
aeruginosa and Klebsiella pneumoniae. The purpose of this investigation is to assess
how different “patterns” of antimicrobial drug use, severity of illness, and geography to
different patterns of carbapenem resistance. The hypothesis is that a significant portion
of the between-hospital variability in rates of CR-PA and CR-KP can be explained by
the combination of antimicrobial drug use, severity of illness, and hospital demographics

1.4 Objectives
1- Determine trends and patterns of overall gram-negative antibacterial drug use
over the study period (2006-2009).
2- Determine proportions, rates, and trends of resistance among CR-PA at each of
the participating hospitals during the study period.
3- Determine proportions, rates, and trends of resistance among CR-KP at each of
the participating hospitals during the study period. Also, identify clinical
microbiology practices related to the isolation of these organisms.
4- Develop a model to determine the magnitude and the significance of association
between the use of specific antibiotics, severity of illness, geography, and
carbapenem-resistant gram-negative bacteria (CR-PA and CR-KP).

5

1.5 Significance and practical implications
The preliminary data, as well as data from others, suggest that carbapenem antibiotic
use and other antibiotic use might be risk factors for CR-PA and CR-KP, but this
relationship is complex. Also, there are no investigations at a national level that have
examined at the role of antibacterial drug use in CR-KP in geographically distributed
hospitals. It is important to understand the relationships between antibiotic use, patient
composition, infection control, and carbapenem resistance to overcome the burden of
these resistant pathogens, especially, with the paucity of new antimicrobial drugs. This
study is the first multicenter study that attempted to assess the impact of aggregate
antibiotic use and other predictors on CR-KP in a relatively large sample of U.S.
academic medical centers. This investigation extend previous investigations of CR-PA
by adjusting for important hospital characteristics (e.g. geographical location, bed size)
The contribution with this study is the assessment of CR-PA and CR-KP current status
and associated risk factors in U.S. academic health centers. If modifiable risk factors
such as, antibiotic use was identified, this could serve as a target of intervention for
antimicrobial stewardship programs to improve resistance patterns in hospitals. In
addition, this investigation could provide hypotheses to conduct further studies, such as
quasi- experiments to assess the effect of the potential modifiable factors on resistance
and to establish a causal relationship, if any.
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CHAPTER 2
Literature Review

2.1 Multidrug-resistant gram-negative bacteria and antimicrobial drug
use
The selection of antibiotic-resistant bacteria has major consequences at both the
patient-and hospital-level. It would increase the risk of colonized patients to develop a
true clinical infection and increase the risk of cross-transmission among hospitalized
patients and further spread of resistance in the community.[ 4,50] While antibiotic
resistance may develop in the absence of antibiotic pressure, antimicrobial usage has
been identified as one of the most important risk factors driving the development of
resistance in many studies.[16] Both overuse of a restricted number of antibiotic agents
and homogeneous use raise the effect of selection pressure.[4, 16] However, data to
support the preceding ‘beliefs’ are few and the existing data are primarily restricted to
single institutions.[13]
Multidrug-resistant (MDR) gram-negative bacteria are often defined as ones that are
resistant to three or more classes of antibiotics through different mechanisms.[1, 2, 4]
The molecular mechanism of multidrug resistance is complicated. The selection
pressure imposed by the use of one antibiotic can result in the selection of bacteria
resistant not only to that particular antibiotic but to other antibiotics, by co-resistance
and cross-resistance mechanisms.[50,51] Mechanisms of acquired resistance include:
gene mutations resulting in altered porin channels limiting penetration of the antibiotic
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into the bacterial cell; production of enzymes that inactivate the antibiotic; alteration of
the target site for the antibiotic; or formation of efflux pumps extruding the antibiotic from
the cell interior before it can act on its target.[52] One example is the overuse of
fluoroquinolone agents, which had led to development of aggressive resistance
mechanisms such as “upregulated efflux pumps” in P. aeruginosa which was resistant
not only to fluoroquinolones but also carbapenems (so-called collateral damage).[51,53]
Actually, all classes of antibiotics except polymyxins are susceptible to extrusion by any
of these efflux systems.[54]
For gram-negative organisms, the impact of infection control measures seems to be
less effective than antibiotic-control measures when compared to gram-positive
organisms such as methicillin-resistant S.aureus (MRSA); thus, the relative contribution
of infection control in nosocomial gram-negative bacteria remains more
controversial.[55] The clinical epidemiology of resistant bacteria may alter over time.
For example, one study found prior fluoroquinolone use to be associated with
fluoroquinolone-resistant E. coli colonization in a relationship that varied significantly by
the study year.[56] Interventions to improve hospital antibiotic use were associated with
a decline in the incidence of antimicrobial resistant bacteria.[57] However, this may
differ substantially across institutions due to the variability of the composition of
patients.[58]
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2.2 Measures of bacterial resistance
Schwaber et al. has argued that the use of proportions of resistant organisms to
evaluate the influence of antibacterial use on resistance can be misleading and
biased.[59] Proportions are dependent on the susceptible and resistant bacteria
populations, whereas the incidence rate of resistance depends only upon the resistant
population. He further explained that antibiotic use likely leads to a decrease in the
absolute number of susceptible organisms, which results in an increase in the
proportion of isolates that are resistant in a certain population. However, this does not
necessarily reflect an increase in the absolute number of resistant isolates or the burden
of resistance.[59] One investigation looking at the impact of ciprofloxacin restriction on
both proportion and incidence rates of resistant isolates of P. aeruginosa found that
ciprofloxacin use declined by 57% and both incidence rates and the proportion of
ciprofloxacin-resistant P. aeruginosa isolates declined significantly. [60] In contrast,
another investigation reported that the incidence rates of MRSA bacteremia in patients
with central lines from 1,684 U.S. intensive care units decreased by nearly 50% over the
10-year period 1997 to 2007, while the proportion (percent) increased by 25%.[61]
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2.3 Carbapenem-resistant P. aeruginosa: status and implications
Overview
P. aeruginosa is a gram-negative rod that is considered to be one of the leading causes
of nosocomial (hospital acquired) infections including healthcare associated pneumonia
and ventilator associated pneumonia. [62,63] Carbapenem antibiotics (e.g. imipenem,
meropenem, and doripenem) continue to be the most consistent effective agents in the
treatment of P. aeruginosa infections. However, it is often difficult to treat P. aeruginosa
with complete eradication due to its ability to develop resistance to multiple classes of
antibacterial drugs, including carbapenems, in the process of treating an existing
infection.[64,65]
Multidrug-resistant P. aeruginosa
Multidrug-resistant P. aeruginosa is often defined as resistance to three or more classes
of antibiotics through different mechanisms including production of beta-lactamases,
upregulation of multidrug efflux pumps, and cell wall mutations. Up-regulated efflux can
concurrently compromise fluoroquinolones and most beta-lactams leaving only
aminoglycosides and carbapenems susceptible, although the latter have high
mutational frequency. A combination of up-regulated efflux, loss of OprD, and
impermeability to aminoglycosides compromise all class of antibiotics except the
polymyxins.[66] Infections with MDR P. aeruginosa are associated with an increase in
rates of morbidity, mortality, the need for surgical intervention, length of hospital stay,
and overall cost of treatment.[67-69]
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Current status
The Surveillance Network Database USA showed an increase in the proportion of P.
aeruginosa isolates that are resistant to multiple antibiotics over the period 1997-2000.
Sixteen percent of these isolates are resistant to ≥ 3 antipseudomonal agents
(imipenem, amikacin, ceftazidime, ciprofloxacin, gentamicin, and piperacillintazobactam). [66] According to the National Nosocomial Infection Surveillance System
(NNIS), the rates of imipenem-resistant P. aeruginosa associated with nosocomial
infections increased by 15% between 1998 and 2002.[70] In contrast, a 2009 report of
10 year trends in antimicrobial susceptibility among 10-15 U.S. hospitals contributing to
the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) surveillance
project found that susceptibility to carbapenems for P. aeruginosa has not changed.[71]
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2.4 Carbapenem-resistant K. pneumoniae: status and implications
K. pneumoniae is a gram-negative, facultative anaerobic bacillus that is responsible for
many infections including urinary tract infections, pneumonia, bloodstream infections,
and intra-abdominal infections. Resistance to penicillin, cephalosporin, and
fluoroquinolone antibiotics has become more common among these organisms over the
years. Resistance to extended-spectrum cephalosporins, which occurs through the
production of ESBLs, has been described worldwide for the past twenty years.[62,63]
Carbapenems have been the most important antimicrobial class for the treatment of
these organisms especially with the increasing incidence of fluoroquinolone resistance
among Enterobacteriaceae including K. pneumoniae, and they are the drug of choice to
treat serious infections caused by ESBLs. [5, 7]
The two most important phenotypes of carbapenem-resistant Enterobacteriaceae in
particular for this investigation in K. pneumoniae are the production of the serinecarbapenemase (KPC) and the metallo-beta-lactamase VIM.[3] Until recently,
resistance to carbapenems has been uncommon among K. pneumoniae in the United
States. However, the emergence of KPC and an Ambler molecular class A enzyme that
utilizes serine at the active site and thereby is able to hydrolyze carbapenems and all
other beta- lactam antibiotics have led to the increased prevalence of carbapenemresistant K. pneumoniae in the U.S.[21] Klebsiella pneumoniae carbapenemase are
encoded by the gene blaKPC, whose potential for inter-species and geographic
dissemination is principally explained by its location within a Tn3-type transposon,
Tn4401. This transposon is a genetic element which is able of inserting into various
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plasmids of gram-negative bacteria. Plasmids carrying blaKPC are frequently
associated with resistance determinants for other antibiotics. [26, 27] Although KPCs
are identified in many gram-negative species, K. pneumoniae is the predominant
species carrying this enzyme.[26] The second common mechanism after KPC is the
production of metallo-beta-lactamnases of ambler class. Acquired metallo-betalactamases (MBLs) most commonly IMP- and VIM-type, are zinc-dependent enzymes
that have been of growing concern over the last decade. This is due to their capacity to
readily hydrolyze most of the beta-lactam antibiotics, including carbapenems, and their
increasing dissemination among gram-negative pathogens.[72]
Another mechanism associated with carbapenem resistance in K. pneumoniae is the
loss of one or both of the porins OmpK35 and OmpK36. Loss of OmpK35 or OmpK36
may increase the MICs of carbapenems, and if the strain also produces betalactamases and carbapenemases, it may result in carbapenem resistance.[73,74]
The first KPC-producing K. pneumoniae isolate was reported in North Carolina in 2001.
Afterwards, outbreaks and transmission of KPC-producing organisms were reported in
the U.S. with geographical variations, as the northeastern part of the nation had several
outbreaks.[30-32] The initial outbreaks were located in New York City. In one
surveillance study conducted in hospitals in Brooklyn in 2003, out of 602 K. pneumoniae
isolates identified a total of 3.3% were found to carry blaKPC. In the next year, two
hospitals in the same city reported outbreaks with an increased number of carbapenemresistant K. pneumoniae. [30] Later on, KPC-producing bacteria have spread
throughout the U.S. and worldwide [33-35]. According to CDC, KPC-producing bacteria
have been reported in 35 states in the U.S. in 2010 compared to one state in 2001.[36]
13

Moreover, 8% of all Klebsiella isolates reported to CDC at 2008 were resistant to
carbapenems compared to less than 1% in 2000. [28] Further, the National Healthcare
Safety Network (NHSN) data from 2006 through 2007 reported the percentage of K.
pneumoniae isolates that were resistant to carbapenems by infection type: central
venous catheter associated bloodstream infection (10.8%); catheter associated urinary
tract infection (10.1%); surgical site infection (5.2%); and ventilator associated
pneumonia (3.6%).[75] In the same MYSTIC surveillance project report mentioned in
section 2.3, the incidence of CR-KP was shown to decline in 2008 compared to the
steep increase in resistance rates observed from 2004 to 2007. [71]

2.5 Clinical outcomes and treatment options of carbapenem-resistant
K. pneumoniae
The spread of KPCs has become a significant problem due to poor outcomes such as,
increased cost, length of hospitalization, frequent treatment failure, and high mortality
rates (30%-57%).[22, 28,29] Poor outcomes resulting from clinical infections with KPCproducing bacteria have been reported since the first outbreaks in New York City
hospitals.[30] In one retrospective cohort study, 44% of CR-KP patients died, whereas
12.5% of carbapenem-susceptible K. pneumoniae patients died. Also, CR-KP isolation
was identified as an independent predictor of in-hospital mortality.[42] Another cohort
study found that KPC-producing K. pneumoniae cases were associated with a greater
than two fold increased risk of death when compared to susceptible K. pneumoniae
cases.[22]
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In addition to poor outcomes associated with KPC-producing K. pneumoniae, treatment
options are very limited. Clinicians are becoming more dependent on polymyxins, and
tigecycline for the treatment of these infections.[76] One literature review, found that
treatment with aminoglycosides, polymyxins combinations, and tigecycline had higher
rates of success compared to carbapenem and polymyxin monotherapy which had
lower rates of success.[77] Polymyxins are in the class of cyclic polypeptides
antibiotics; polymyxin B and E (colistin) are available in the market. In vitro
susceptibility of KPC-producing isolates to polymyxins is 90-100 %. Polymyxin use is
infrequent; mainly because of their associated neurotoxicity and nephrotoxicty.[27, 77]
Combining polymyxins with other antibiotics in treating KPC-producing isolates has
been associated with a better success rate. In one study, 25% of patients treated with
polymyxin monotherapy developed resistance during treatment, whereas none of the
patients treated with a polymyxin-tigecycline combination developed resistance.[78]
Tigecycline is a novel semisynthetic glycylcycline, which is used in the treatment of
severe infections caused by multidrug-resistant gram-negative bacteria including KPCproducing bacteria. [21, 27] Although in vitro susceptibilities of KPC-producing bacteria
are 100% against tigecycline, treatment failure has been reported. According to one
literature review, five out of seven patients were treated successfully with tigecycline.
One case of recurrent infection was associated with a tigecycline MIC increase from 0.5
to 2 mg/L. However, tigecycline has low serum concentrations and urine
concentrations. [26]
Aminoglycosides are considered valuable therapeutic options for treating KPCproducing bacteria, but resistance is increasing towards these agents; susceptibility
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should be always evaluated, and preferably these agents should be used in
combination. [26, 27]

2.6 Detection of carbapenemase-producing K. pneumoniae
Detection of KPCs by the microbiology laboratory represents a challenge as they may
not be detected by routine antibiotic susceptibility testing methods. [21, 25, 27] A
number of KPC-producing bacteria have been reported as susceptible to carbapenems
as they have carbapenem MICs that remain in the susceptible range.[21, 25] The
presence of KPC does not always result in high-level resistance to carbapenems, but
may represent MIC elevations that stay within the susceptible or intermediate range.[77]
Experts consider detection of KPC-producing bacteria susceptibility to be difficult with
any microbiological technique.[21] Detection of KPC using automatic antibiotic
susceptibility testing methods was shown to provide inconsistent results and considered
problematic. Hence, more complicated, confirmatory, and phenotypic methods are
needed to confirm KPC. Confirmatory methods include: modified Hodge test;
polymerase chain reaction (PCR); inhibitor based test; EDTA-based synergy tests; and
Etests.[25, 77, 79-83] The gold standard method to confirm the presence of a KPC is
spectrophotometry followed by PCR of the blaKPC gene.[21, 77] However, this method
is time consuming, costly, and requires reference laboratories to verify results.[21,77]
Susceptibility testing of KPC-producing bacteria using Etest method is considered
difficult to interpret as the scattered inner colonies can make the inhibition zone difficult
to read.[21, 77, 79] Modified Hodge test has high sensitivity (95%-100%) to detect
diffusible carbapenemase and it’s the only method recommended by the Clinical
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Laboratory Standards Institute (CLSI) in 2009 to confirm KPC-producing bacteria. [84]
That is, for an Enterobacteriaceae with elevated MICs to carbapenems (2 -4 µg/mL) or a
reduced disk diffusion zone, it should be tested with MHT to confirm
carbapenemases.[84] The test is performed by culturing susceptible isolates on a
Mueller-Hinton plate. Then the carbapenem disk is placed in the center, and isolates
suspected of producing carbapenemases are streaked from the disk to the outer margin
of the plate. Growth of bacteria like K. pneumoniae near the disk or along the isolate
streak indicates the presence of carbapenamases (figure 2.1, A).[21, 26] However, the
interpretation of this test can be difficult for some isolates resulting in false positive
detection. [21, 25, 26] More sophisticated techniques like PCR-based techniques are
more specific and sensitive with a major advantage of shorter time to results but require
technique knowledge, equipment, and are more costly. [21, 84] Recently, in June 2010
the CSLI lowered carbapenems breakpoints, to better detect KPCs without the need to
perform the modified Hodge test. [85] Table 1.1 describes the old and the new
breakpoints.
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Table 2.1 Clinical and Laboratory Standards Institutes breakpoints for carbapenems and
Enterobacteriaceae [80]
Older CLSI breakpoints

Revised CLSI breakpoints

(M100-S19) MIC(µg/mL)

(M 100-S20) MIC (µg/mL)

Agent

S

I

R

S

I

R

Imipenem

≤4

8

≥16

≤1

2

≥4

Meropenem ≤4

8

≥16

≤1

2

≥4

Ertapenem

≤2

4

≥8

≤0.25 0.5

≥1

Doripenem

….

….

….

≤1

≥4

2

Susceptible = S, Intermediate = I, Resistant=R, Minimum inhibitory concentration= MIC
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Figure 2.1 The modified Hodge test Mueller-Hinton agar plate. The MHT identified
Isolate A as a positive KPC-producing isolate, while isolates B, C, and D were not KPCproducers. Adapted from Anderson et al. (2007). [25]
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2.7 The role of hospital infection control
In general, prior antibiotic use has been strongly implicated in the development of
resistance. However, exposure to resistant bacteria from other sources, like other
patients, healthcare personnel, or inanimate objects has also been associated with the
emergence of resistant bacteria.[86]
For gram-negative organisms, the impact of infection control measures seems to be
less effective than antibiotic control measures when compared to gram positive
organisms such as MRSA, thus the relative contribution of infection control in
nosocomial gram-negative bacteria remains more controversial.[61] However, enforced
infection control measures were found to decrease the spread and the incidence of
gram-negative bacteria like carbapenem-resistant Enterobacteriaceae (CRE) in many
outbreaks. For example, an implementation of a comprehensive infection control
intervention, composed of intensified infection control measures with routine rectal
surveillance, was successful in reducing the incidence of CR-KP in an intensive care
unit where strains producing the carbapenemase KPC were endemic.[87] A quasi
experiment found the use of active surveillance and contact precautions, as part of a
multifactorial intervention, to be an effective strategy to decrease rates of nosocomial
transmission of carbapenem-resistant K. pneumoniae colonization or infection.[88]
Another quasi-experiment in a long-term acute care hospital showed the implementation
of bundled interventions: daily 2% chlorhexidine gluconate baths for patients; enhanced
environmental cleaning, surveillance cultures at admission; serial point prevalence
surveillance (PPS); isolation precautions; and training of personnel resulted in
preventing horizontal spread of KPC‐producing gram‐negative rods, despite ongoing
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admission of patients colonized with KPC producers.[89] However, there is a lack of
information about antimicrobial restriction efforts and their influence on the incidence of
CRE, but some researchers believe that antibiotic stewardship should focus on
reduction of overall antibiotic use, not on limiting specific agents.[90]

2.8 Confounding factors
Confounding is an important concept in epidemiological studies; it occurs when a third
variable(s) influence the relationship between an exposure or treatment and an
outcome.[39] This is considered problematic because the estimate of association
between exposure and disease include the contribution of both the exposure and the
confounder. A confounding variable must be associated with the outcome variable; it is
associated with the exposure but not caused by exposure. The presence of confounding
can result in overestimation of the true association, underestimation of the true
association, or change in the direction of the association between exposure and
outcome.[39, 40] Confounding by indication in particular, is the most common type of
confounding in observational pharmacoepidemiological studies. It’s defined as a “type of
selection bias in which the indication of a drug may influence the allocation of a patient
into one or another of the comparison groups”.[91] Controlling for a confounder variable
in study design and/or data analysis is crucial to avoid confounding bias and to rule out
its effect on the causal association between exposure (treatment) and the outcome of a
pharmacoepidemiological study.
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Although antibiotic use is considered a major driver for development of antibiotic
resistance, the nature of this relationship is complex.[16] This is due to the presence of
other confounding factors that may influence bacterial resistance in a hospital setting.
Failure to deal with these confounders will make it difficult to evaluate and interpret the
impact of antibiotic use on resistance. Some of these confounding factors are measured
by an administrative database, and some are not measured. A brief description of
these confounding factors follows.
One potential confounder is the use of antibiotics other than those studied. It is possible
that more than an individual class of antibiotics use will aid in promoting resistance. The
microbiological outcomes are carbapenem-resistant gram-negative bacteria which are
often multidrug resistant. [50] The selection pressure imposed by the use of one
antibiotic can result in the selection of bacteria resistant not only to that particular
antibiotic but to other antibiotics, by co-resistance and cross resistance
mechanisms.[50,51] All broad spectrum antibiotic classes used to treat the bacteria of
interest were included in the model selection and adjusting processes.
Geographic location plays an important role in the distribution of many MDR gramnegative bacteria, in particular CR-KPs, which are abundant in the Northeast areas, so
elevated rates of resistant bacteria in certain hospitals could be due to their presence in
certain geographical locations.[92] Infection control efforts play a major role in bacterial
resistance, poor infection control measures can result in the spread of antibiotic
resistance.[15] Also, for hospitals with a strict infection control policy, it is expected it
will have lower rates of resistance transmission. However, there is no quantitative
measure of the quality and quantity of infection control in the hospital. Additionally,
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resistant organisms brought into the hospital and cross transmission may confound the
relation between antibiotic use and resistance. Patients infected with MDR bacteria
transferred from another hospital may impact the resistance rate in that hospital.[24]
However, this confounder cannot be adjusted for.
Antimicrobial stewardship programs perform restriction policies for some formulary
drugs, cover appropriate choice of empirical therapy, and assign proper dosage and
duration of therapy. Proper implementation of stewardship would aid in lowering
antibiotic resistance.[11, 12] Thus, it is expect for hospitals with a restriction policy to
have lower rates of resistance. Another potential confounder is the underlying severity
of patient illness, as severely ill patients will presumably be at greater risk to develop
resistance, because they have impaired host defenses and will receive more antibiotics
compared to low risk patients.[17] Finally, there are as in any research unknown
confounder(s).
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2.9 Previous Investigations
2.9. 1 Carbapenem-resistant P. aeruginosa

Several studies have been conducted to identify risk factors associated with CR-PA ;
most of these investigations were single center case control studies as summarized in
table 2.2. One single center case control study found no association between prior
antibiotic use (including carbapenems) and acquisition of CR-PA in a multivariable
model.[93] The authors considered antibiotic use at the time of study thereby ignoring
earlier use of hospital antibiotics. Only admission frequency and presence of Foley
catheters were identified as significant risk factors. The authors believed that the
observed high proportion of CR-PA in their institution was driven by a consequence of
transmission of an organism already resident in their hospital rather than by selective
antibiotic pressure. Another investigation in two centers collected 253 isolates of CRPA between 2001 and 2006, found prior carbapenem, fluoroquinolone, extendedspectrum cephalosporin, and anti-anaerobic agent use in the preceding 30 days of
culture sampling to be significantly associated with CR-PA in univariate analysis.[23]
However, prior carbapenem use, transfer from outside facility, and duration of
hospitalization prior to culture sampling were the only significant independent factors
associated with CR-PA in the multivariable model. Also, ICU stay was used as a
surrogate for severity of illness. Another single center case control study found that
exposure to carbapenems 15 days before isolation and receiving mechanical ventilation
for more than 48 hours to be associated with MDR P. aeruginosa (defined as resistant
to ceftazidime, ciprofloxacin, piperacillin, and imipenem) in a multiple logistic regression
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analysis.[45] Exposure to carbapenems within 14 days prior to isolation of positive
cultures of CR-PA and renal failure were independently associated with CR-PA in
multivariable analysis, in a single center case control study.[46]
The limitations of these case control studies investigating risk factors of CR-PA are the
small sample size, single center institutions in which the stewardship and infection
control practices may vary, impacting the generalizability of the results. The association
between antibiotic use and resistance appears in many of the univariate analysis but
when conducting a multivariable model many of these associations seem to fade. Some
of these multivariable models adjusted for several confounders, but most relied on ICU
stay as a measure of SOI rather than using other standard comorbidity-SOI indices.
One ecological single center study investigated the correlation between antimicrobial
use density (AUD), which they used as a surrogate for defined daily dose /1000 patientdays-of carbapenem and carbapenem-susceptible P. aeruginosa in patients when
followed every six months for the period between 2006 and 2008. They found a
significant negative correlation between meropenem susceptibility in P. aeruginosa and
total AUD of meropenem and doripenem. It wasn’t clear how they adjusted for the
dependency between their observations and how the correlation analysis was
conducted.[94]
One retrospective, longitudinal study conducted was a time series analysis with months
as a unit of analysis over the period 2001-2005 that evaluated the association between
carbapenem use (defined daily dose) and CR-PA incidence rates and proportions in a
single hospital. In their multivariate analysis, the use of group 2 carbapenems
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(imipenem, meropenem, and doripenem) was highly associated with CR-PA
proportions. However, ertapenem use was not associated with CR-PA.[95]
Finally, a multicenter study (25 hospitals) investigated the role of ertapenem use on CRPA at an aggregate level and found no significant association between change in
ertapenem use, carbapenem use, fluoroquinolone use and CR-PA. [47] They only
adjusted for other antipseudomonal antibiotics in their model.
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Table 2.2 Carbapenem-resistant P. aeruginosa previous studies
Author

Study design

Setting(s)

Risk factors

Eagye et al.,

Case-control

Single

Admission frequency, Foley

center

catheters

Two

Carbapenem use, transfer from

centers

outside facility, duration of

2009
Lautenbach et

Case-control

al., 2010

hospitalization
Cao et al., 2004

Zavascki et al.,

Case-control

Case-control

2005

Single

Carbapenem use, mechanical

center

ventilation

Single

Carbapenem use, renal failure

center

Carmeli et al.,

Ecological,

Single

2011

longitudinal study

center

Eagye et al.,

Ecological,

Multicenter

2010

longitudinal study
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Carbapenem use

None

2.9.2 Carbapenem-resistant K. pneumoniae

CRE was rare until 2006; however, the incidence has been increasing since then, with
outbreaks reported in the northeastern United States and spread of CRE described in
other countries over the world.[90] Summary of the studies that investigated CR-KP are
displayed in table 2.3.
One case control study where cases were patients with KPC-producing K. pneumoniae
compared with control subjects with carbapenem-susceptible K. pneumoniae was
conducted in two medical centers. In the multivariable analysis, only APR-DRG
extreme illness category, prior fluoroquinolone use, and prior extended spectrum
cephalosporin use were significantly associated with isolation of KPC-producing K.
pneumoniae. [42] Prior antibiotic exposure was defined as at least two days of therapy
administered during the 30 days prior to the culture. The authors mentioned that a very
few patients had a history of carbapenem use (1.1%). As such, prior use of
carbapenems as a risk factor for KPC production in K. pneumoniae isolates cannot be
excluded.
In a single center case control study, patient conditions like malignancy, neurologic
disease, poor functional status, high Charlson comorbidity index score, presence of
central venous line, Foley catheters, mechanical ventilation, and ICU stay were
associated with carbapenem-resistant K. pneumoniae in univariate analysis.[29] In
addition, cases were shown to have received more antibiotics than controls. However,
the multivariable model identified prior use of fluoroquinolones to be the only antibiotic
independent predictor of carbapenem-resistant K. pneumoniae isolation along with poor
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functional status and ICU stay. Carbapenem use could not be included in the model as
none of the controls received carbapenems.
Another matched case control study in two health centers compared carbapenem –
resistant K. pneumoniae to carbapenem-susceptible K. pneumoniae. The following were
identified as predictors of CR-KP in univariate analysis: history of Chronic Obstructive
Pulmonary Disease (COPD); admission to the ICU; mechanical ventilation; prior use of
antipseudomonas penicillin; fluoroquinolones; glycopeptides; carbapenems; presence of
tracheotomy; and having surgery with the use of a foreign body.[43] Prior antibiotic use
was identified as an exposure that occurred only during the hospitalization in which the
infection developed and the antibiotic had been administered for at least 3 consecutive
days prior to the development of the infection. The multivariable analysis for matched
data showed that prior use of fluoroquinolones and antipseudomonal penicillins were
independent risk factors for CR-KP infections. Another matched case control study
identified 99 cases of CR-KP and 99 control with carbapenem-susceptible K.
pneumoniae.[22] In the univariate analysis, transplant recipient, mechanical ventilation,
ICU stay, length of stay before infection, prior use of cephalosporin, beta-lactam and/or
beta-lactamase inhibitor, carbapenem, and aminoglycosides were associated with CRKP. The multivariable model had shown prior exposure to cephalosporins,
carbapenems, and longer length of stay before infection to be significantly associated
with CR-KP acquisition. Antibiotic exposure was identified during patient hospitalization
or within 3 months before the diagnosis of K. pneumoniae infection.
Finally, a case control study design found that ICU admission within two weeks, tracheal
intubation, mechanical ventilation, exposure to carbapenems, fourth generation
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cephalosporins, piperacillin-tazobactam, and glycopeptides to be associated with the
isolation of CR-KP in univariate analysis.[44] The multivariable model found only ICU
admission, prior exposure to carbapenems, and glycopeptides to be independently
associated with CR-KP isolation. However, the sample size was relatively small, and
resistance mechanisms were not identified.
To summarize, prior use of carbapenems, fluoroquinolones, and extended- spectrum
cephalosporins are associated with isolation of carbapenem resistant CR-KP as
identified in several case control studies. Most of the studies had a small sample size
and were single centered which limit their generalizability, especially as infection control
measures vary among these institutions.
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Table 2.3 Carbapenem-resistant K. pneumoniae summary studies
Author
Gasink et al., 2009

Study design
Case-control

Setting(s)
Two centers

Schwaber et al.,
2008

Case-control

Single center

Falagas et al., 2007

Case-control

Two centers

Fluoroquinolones,
antipseudomonal
penicillins

Patel et al., 2008

Case-control

Single center

Carbapenems,
cephalosporins,
length of hospital
stay

Wu et al., 2011

Case-control

Single center

ICU admission,
carbapenems,
glycopeptides

31

Risk factors
APR-DRG extreme
category,
fluoroquinolones,
extended-spectrum
cephalosporins
Fluoroquinolones,
poor functional
status, ICU stay

CHAPTER 3
METHODS
3.1 Study design
This was an ecological longitudinal observational study of hospitals within the University
Health System Consortium (UHC) database. The outcomes of interest were
carbapenem- resistant Pseudomonas aeruginosa (CR-PA) and carbapenem-resistant
Klebsiella pneumoniae (CR-KP). The exposures of interests included hospitals’
antibacterial drug use, case mix index (CMI), aggregated 3M All Patient Refined
Diagnosis Related Group (APR-DRG) Classification System, and hospital
demographics (bed size and geographical location).

3.2 Data source
The UHC is a national alliance of 103 academic medical centers and 206 of their
affiliated hospitals representing approximately 90% of the nation's non-profit academic
medical centers. The UHC provides a mechanism for collaboration for research across
academic medical centers, which are geographically distributed throughout the U.S. A
subset of UHC hospitals participate in the Clinical Resource Manager (CRM) Database
and will serve as the data source. It contains Uniform Billing (UB-92) data, inpatient
medication use from charge transaction masters, and billing files from participating UHC
members. Patient records contain detailed information on inpatient care, and this
includes primary and secondary diagnoses (in International Classification of Diseases,
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9th Revision, Clinical Modification [ICD-9-CM] format), inpatient procedure codes (in
ICD-9-CM format), patient demographic information (age, race, and gender), and
hospital demographic information (bed size and geographical location). [96] The
database also contains admission and discharge dates as well as information on
comorbidities, severity of illness, physician specialty, length of stay (LOS), costs, and
clinical outcomes such as inpatient mortality and complications rates. Antibacterial drug
use was used from this database; the validation of UHC database and its assessment of
hospital antibacterial drug use have been described. [48]

3.3 Antibacterial drug Use
The UHC database provides antibiotic use data that are based on charges for patients
not the overall amounts the institution purchases. Antibacterial agents whose use has
been reported as risk factors for the development of CR-Pa and CR-KP as identified in
the literature review are listed in table 3.1. The systemic use of these antibiotics in adult
(>=18) inpatients discharged between January 1, 2006 and December 31, 2009 was
obtained from billing records and reported as days of therapy per 1000 patient days
(DOT/1000 PDs). Any single dose of antibiotics that was received by a patient was
reported as one DOT regardless of multiple dose administration. For example,
administration of gentamicin every 8 hours for 3 doses, or administration of the entire
daily dose every 24 hours, would be counted as one DOT. The defined daily dose
(DDD) method of reporting drug use is adopted by World Health Organization (WHO),
but important deficiencies were presented when compared to DOT method.[97] In
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addition, CMI, geographic location, proportion of patients in each of the four APR-DRG
categories, and bed size for each hospital were obtained for the study period.
Table 3.1 Systemic use of antibacterial drugs categorized into groups
Antibacterial Group

Antibacterial agents

Carbapenems

Imipenem, meropenem, ertapenem,
doripenem

Fluoroquinolones

Ciprofloxacin, levofloxacin, moxifloxcacin,
gatifloxacin

Third-and fourth-generation

Ceftriaxone, cefotaxime, ceftazidime,

cephalosporins, monobactams

cefepime, aztreonam

Aminoglycosides

Gentamicin sulfate, tobramycin, amikacin

Antipseudomonal Penicillins

Piperacillin-tazobactam, ticarcillinclavulanate
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3.4 Severity of illness
Measuring severity of illness using aggregate level data is not a well established
concept. Overall hospital CMI [the average of DRG weights for all of an individual
hospital’s DRG-paid Medicaid claims] had been considered an indicator of the intensity
of hospital resource utilization and can be used to compare hospital performance, but it
is less sensitive to the severity of illness from a clinical perspective. [98, 99] In addition
to CMI, another severity of illness measure based on the APR-DRG classification
system was used in this present investigation; this measure reflects the clinical
complexity of a patient population. The underlying clinical principle of the APR-DRGs is
that the severity of illness and risk of mortality of a patient depends to a great extent on
the patient’s underlying characteristics. This system assesses the relative severity of a
patient’s illness based on the severity level of the secondary diagnoses and interactions
between secondary diagnoses, age, principal diagnosis, and certain procedures. There
are four subclasses of SOI (minor, moderate, major, extreme) based on the presenting
DRG.[100, 101] The UHC database includes the number of patients within each of the
four categories for each participating hospital for each year. Hence, the proportions of
patients within each category for each year were calculated. The APR-DRG proportions
and CMI were highly correlated, especially the extreme category of the APR-DRG.
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3.5 Antimicrobial susceptibility

“Whole house” antibiograms from all hospitals for which antibacterial drug use data
were obtained were requested from 2006 through 2009. An email request was sent to
50 hospitals accompanied by an online survey for which antibiotic use data from 2006 to
2009 were obtained. Only antibiograms with a full calendar year of susceptibility data
from all clinical sources, at least 30 isolates for each organism and those including total
number of isolates and proportion of susceptible isolates were included in the final
dataset. The desired outcomes, carbapenem (imipenem or meropenem)-resistant P.
aeruginosa and K. pneumoniae were calculated from theses antibiograms. Both
proportions and rates of resistance for CR-Pa and CR-KP were recorded. The resistant
proportion was the number of resistant isolates divided by the total number of isolates,
and the resistant incidence rate was the number of resistant isolates per 1000 adult
patient discharges, and per 1000 adult patient days (PDs). The number of adult
discharges and adult patient days were obtained from the UHC database.

3.6 Survey
Hospitals that participated in the UHC-CRM for which the antibacterial use data were
obtained from 2006 to 2009 were invited to complete a survey in January 2011 (with
follow-up requests to non-responders in April 2011 and August 2011). The online survey
was sent to each of the 50 hospitals along with the request for new antibiograms. Each
hospital contact, usually clinical pharmacy infectious disease specialists but may also
include infectious disease physicians, clinical microbiologists, or infection control
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practitioners, received an online survey by REDCap (Research electronic data capture)
to obtain data that are not available to us through UHC. REDCap is a secure, webbased application designed to support data capture for research studies, providing: 1)
an intuitive interface for validated data entry; 2) audit trails for tracking data
manipulation and export procedures; 3) automated export procedures for seamless data
downloads to common statistical packages; and 4) procedures for importing data from
external sources.[102] The online survey was divided into three parts. The first part
requested additional information regarding susceptibility testing methods and
antibiograms construction, including the inclusion/exclusion of duplicate isolates,
method(s) of routine susceptibility testing, policy regarding surveillance cultures and
intermediate susceptible isolates. The second part requested information about
carbapenem-resistant Enterobacteriaceae and carbapenem-resistant K. pneumoniae
including hospital encounter of such organisms in the past five years, rate of isolation in
the past year, source (e.g. transfer from another hospital and/or nursing home), and
microbiological technique used to identify and/or confirm CRE. In order to compare the
number of isolates of carbapenem-resistant K. pneumoniae obtained from hospital
antibiograms to the number of resistant isolates obtained from the clinical microbiology
laboratory in each hospital a question about the reflection of the rate of isolation of
these bacteria in hospitals antibiograms was included in the survey. The third
component was about antimicrobial stewardship programs (ASP), specifically about the
role of ASP in managing CR-KP cases, isolation procedures and measures with such
cases, and restriction policies for carbapenems. It was also asked if there had been any

37

changes in the ASP policies over the current study period. The survey is provided in
appendix A.

3.7 Data collection
Each hospital was offered $100 per year of antibiograms and for the completion of the
online survey. Antibiotic use data, CMI, APR-DRG and other demographics were
available for 50 hospitals for the period of 2006-2009. The antibiograms/survey requests
were sent to all contacts of the 50 hospitals in the period of January 2011, a second
round of requests was sent to non-responders by April 2011, and a final round of
reminders was sent by August 2011. Of the total 50 hospitals approached, 40 hospitals
provided antibiograms, thirty of which completed the online survey. The outcome data,
proportions and rates of CR-PA and CR-KP were calculated directly from the
antibiograms. The UHC obtained variables are listed in table 3.2.
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Table 3.2 Description of the analysis variables obtained by UHC
UHC data variable

Unit

Symbol used SAS
code

Fluoroquinolones

DOT/1000 PDs

Fluoroquinolones (except moxifloxcacin)

FQ
FQMo

Carbapenems

DOT/1000 PDs

Carbapenems (except ertapenem)

CB
CBE

Aminoglycosides

DOT/1000 PDs

AG

3rd& 4th generation cephalosporins

DOT/1000 PDs

CEPHt

Antipseudomonal cephalosporins

CEPHn

Piperacillin-tazobactam, ticarcillin-clavulanate

DOT/1000 PDs

ExPen

Hospital bed size

Number of

Bedsize

beds
Hospital geographic location
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Name

Location

Mid-Western

1

Mid-Continent

2

Southeastern

3

Mid-Atlantic

4

Western

5

New-England

6

Hospital CMI

No unite

CMI

Proportion of patients with APR-DRG score

Proportion

minor

Proportion

moderate

Proportion

major

Proportion

extreme

Carbapenem restriction

Yes/ No

restriction

Removal of duplicate isolates

Yes/No

dup

Including surveillance cultures

Yes/No

surv

minor
Proportion of patients with APR-DRG score
moderate
Proportion of patients with APR-DRG score
major
Proportion of patients with APR-DRG score
extreme
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3.8 Modeling longitudinal (repeated measures) data
Longitudinal data
This analysis involves longitudinal measures of bacterial resistance and antibiotic use
over a four-year period. In this set of longitudinal data (repeated measures), the
assumptions of independence between any two observations from different hospitals
are valid, as this sample represents a random sample of UHC hospitals. In contrast, any
two observations from the same hospital are correlated as they will have the same basic
characteristics and accordingly they will not be independent.[103] Modeling correlated
data as if they were independent can result in incorrect inferences of the regression
parameters due to underestimation of standard errors and insufficient
estimators.[103,104] Therefore, there are specific statistical methods to model
longitudinal data.
Mixed models, generalized mixed models, and generalized estimating equations are all
methods used to analyze longitudinal data and will be explained in this section. All of
these methods share one common feature, which is the predetermination of the
covariance structure to account for correlation between observations. [105,106] Table
3.3 compares these methods and their use in SAS.
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Table 3.3 Comparison of most common statistical methods to analyze longitudinal data
Model

LMM

Output

Types of

variables

inputs,
effects

Interval

Goodness

Missing

estimate

of fit

data

parameters

criteria

Need to be

AIC,

interval,

specified in

AICu, BIC

random

the model

Categorical,

Assumptions Method to

Normality

MAR

effects
GEE

Categorical, Categorical,

Exponential

Need to be

QIC ,

interval

family

specified in

QICu

interval,
combine fix

MCAR

the model

and random
effects
GLMM Categorical, Categorical,
interval

interval,

Exponential

Need to be

Pseudo-

family

specified in

AIC

random

the model

effects

MAR

PseudoBIC

Note: Linear mixed models (MM), Generalized estimating equations (GEE), Generalized
Linear mixed models (GLMM), Akaike’s information criterion (AIC), Schwarz’s Bayesian
information criterion (BIC), pseudo-Akaike’s information criterion (pseudo-AIC), pseudoSchwarz’s Bayesian information criterion (pseudo-BIC), quasi-likelihood under the
independence model criterion (QIC), missing at random (MAR), missing completely at
random (MCAR).
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The following section will provide an overview of each of these statistical methods.

Linear Mixed models (LMM)
These models contain both fixed and random effects and perform analysis by way of
structured covariance models. The LMM procedure estimates parameters by restricted
maximum likelihood (REML) technique which was introduced by Patterson and
Thompson (1971). The restricted likelihood is maximized under the assumption of
normal distribution of the data. All available data can be used with LMM as long as any
missing data are missing at random (MAR).[107,108] Covariance parameters are
estimated by the method of moments though solving expressions for expected mean
squares.[107,108] Model fit criteria usually involves Akaike’s information criterion (AIC)
and Schwarz’s Bayesian information criterion (BIC). Both can be used in the model
selection process. [107-109]

The notation for linear mixed models is:

y  X  Z   e

Where y , X ,  and e are as defined in the fixed effects model, and

  (1,  2, . . .,  q)  random effect/coefficient parameters. The Z is a second design
matrix with dimension n×q giving the values of random effects corresponding to each
observation.[108]
A covariance structure must be explicitly specified to account for within-subject
correlation by specifying how observations within a subject or cluster are correlated with
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each other. Misspecification of the covariance structure can yield to invalid results.[107110] Examples of most commonly used correlation matrices are described in table 3.4

Generalized linear mixed models (GLMM)
The GLMM is an extension of the family of generalized linear models (GLM). These
models have the ability to account for within-subject correlations by explicitly specifying
a working correlation matrix and are considered subject-specific models.[108,111] The
GLMM inflates GLMs by including some variables as random effects. It allows the within
subjects dependence to differ from one subject to another by means of the random
variation of the linear combination of covariates and the residual variation. The random
variation can be expressed in the random intercept and random slope. [108,111,112]
The change of an individual’s response can be evaluated by including these random
effects in the model; consequently they are considered to be subject-specific models.
Similar to linear mixed models, GLMM handles missing data if they were missing at
random. Thus, for missing data, the working correlation from data containing missing
values can be estimated by using all the available pairs of data. Moreover, generalized
mixed models by include variables of non-normal distribution, in particular when the
response variable has a distribution from one of the exponential family of distributions.
For example, binary, binomial, Poisson, negative binomial, normal, beta, gamma and
inverse Gaussian distributions are all members of the exponential family.[108,111, 112]
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The notation for GLMM is:

g ( )  X  Z  e
Where  is the vector of expected means of the observations and is linked to the model
parameters by a link function, g , X , and Z are the fixed and random effects design
matrices. Moreover,  is the vector of fixed parameters and  is the vector of random
effects parameters.[108]

The GLMM implements the estimation technique using residual pseudo-likelihood and
was proposed by Wolfinger and O’Connell (1993) with a subject specific
expansion.[112-114] This method is referred to as ‘pseudo-likelihood’ because the
likelihood function maximization is based on the pseudo variable (pseudo data) and not
that of the original data. Consequently, model fitting criteria such as pseudo-AIC and
pseudo-BIC are not comparable to the log-likelihood criteria used in mixed models and
should be interpreted cautiously.[108,112-114] In order to fit GLMM models, an
appropriate distribution, link function, and working correlation structure should be
specified.
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The Generalized Estimating Equations (GEE)

The GEE method was introduced by Liang and Zeger 1986 for analyzing correlated
response variables in longitudinal data. The GEE model extended generalized linear
models by assuming a known function of the marginal expectation of the outcome
variables by using the quasi-likelihood approach.[115] The GEE model accounts for
within-subject correlations by explicitly specifying a working correlation matrix for
different types of response data, in particular the exponential family of
distributions.[115,116] Also, the GEE method handles missing data as if they were
missing completely at random (MCAR). [115,116]
The notation for GEE is:
K

S(  )   Di Vi1 (Yi  i (  ))  0
i 1

Where

Di 

i


Since

g( ij )  x ij 
where g is the link function, the p  n matrix of partial derivatives of the mean with
respect to the regression parameters  for the i th subject.[115,117]
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The GEE model is also known as a “marginal” model as it models a known function of
the marginal expectation of the response variable as a linear function of the explanatory
variables.[116,118] The effect of the between-subjects factor is modeled separately
from the within-subjects correlation. Thus, the interpretation of the parameters does not
depend on a particular subject, but rather it is valid for the whole population of possible
subjects in the study. Accordingly, these parameters can be referred to as populationaveraged parameters.[115,116,118] Regression coefficients of such model describe
the average population response curve. One unique advantage with GEE models is the
robust covariance matrix concept proposed by Liang and Zeger (1986) which entails
that as long as the mean model is correct, the parameter estimates are consistent as
the number of subjects (hospitals) becomes large.[115,116,119,120] This is of
considerable importance in cases of correlation structure misspecification where one
can still obtain consistent parameters estimates. The quasi-likelihood under the
independence model criterion (QIC) proposed by Pan (2001) is an extension of the AIC
and can be used in model fit assessment.[121,122]
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Table 3.4 Commonly used correlation matrices with correlated observations [105,110]
Correlation structure

Definition

Independence

Each observation in a subject is completely uncorrelated
with every other observation in that subject

Exchangeable

Each observation within a subject is equally correlated with

(Compound

every other observation in that subject

Symmetry)
Autoregressive

For two observations taken close in time within a subject,
they will be more closely correlated than two observations
taken far apart for the same individual.

Unstructured

No assumption is made about the magnitude of correlation
between any two pairs of observation.
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3.9 Statistical analysis
3.9.1 Software

Statistical analyses were performed using SAS (version 9.2; SAS Institute, Cary, NC)
and JMP (version 8.0; SAS Institute, Cary, NC). JMP was mainly used for descriptive
statistics while SAS was used for the GEE analysis. All tests were two-tailed; a p-value
< 0.05 was considered significant.

3.9.2 Summary statistics

Descriptive statistics including the mean, standard deviation, and full range were
calculated for antibiotic use groups. The median, interquartile range, and full range were
calculated for CR-KP rates and proportions and the mean, standard deviation, and full
range were calculated for CR-PA rates and proportions.
Mixed model ANOVA method was used to report trends in antibiotic use and resistance
rates and proportions of CR-PA and CR-KP over the study period. The mean use of
carbapenem use and rates of CR-PA were compared among hospitals that did vs. did
not restrict carbapenem agents using the Wilcoxon Rank-Sum Test.

3.9.3 Modeling carbapenem-resistance gram-negative bacteria

The analytical approach used in this investigation was generalized estimating
equations. The QIC value was used to determine the best distribution and link functions,
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as well as working correlation structure. [121,122] For the CR-PA rates (1000 PDs), a
normal distribution, identity link, and first-order autoregressive working correlation
structure were selected after comparing QIC values (the smaller the better). CR-PA
proportions are considered limited range variables; they are limited between 0 and 1.
Falsely assuming normality in such cases can lead to incorrect results.[119] Hence, a
binomial distribution, logit identity, and first-order autoregressive working correlation
structure were selected for CR-PA proportions.
Given that almost half of the CR-KP data were of zero value, using proportion or
incidence rate was not feasible. Therefore, CR-KP data were treated as a binary
outcome (present vs. absent). First, a cut point of a proportion ≤ 1% was considered an
“absence” response and >1% was considered a “present” response, however, only
24% of the observations were “present” outcome and this resulted in some
convergence/ iteration issues in running the model through SAS. Thus, the raw number
of isolates was used to generate a binary categorical variable as follows: if a hospital
(according to its antibiogram) encountered less than 5 isolates per year then it was
considered as an “absent” response, if the hospital encountered 5 or more isolates per
year then it was considered as a “present”. Consequently, 41% of observations had the
outcome “present”. Binary distribution, logit link, and 1st order autoregressive working
correlation structure were chosen for CR-KP.
Each of the three outcomes was analyzed separately. Variables were added to the
model based on their importance according to previous findings in literature and
preliminary analysis of the data. For CR-PA rates and proportions the following
explanatory variables were included in the model selection process: fluoroquinolones
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(ciprofloxacin, levofloxacin, gatifloxacin); carbapenems (imipenem, meropenem,
doripenem); antipseudomonal penicillins (piperacillin-tazobactam, ticarcillinclavulanate); antipseudomonal cephalosporins (ceftazidime, cefepime, aztreonam);
aminoglycosides (gentamicin, tobramycin, amikacin); and hospital CMI, patientproportion within the APR-DRG categories. The patient-proportions within the APRDRG categories were not combined with CMI. Variables were entered and models
were compared using QICᵤ. QICᵤ is a simplified version of QIC that can be used to
select the most parsimonious model, that is, the best model is the one with smallest
QICᵤ.[122] A Huber-White sandwich estimator (robust estimator) was used as a way to
ensure that the variances were robust. Specifically, robust variances are important as
they provide accurate assessments of the sample-to-sample variability of the parameter
estimates even if the model is misspecified.[115,116,118] After selection of the “best
model”, adjusting for potential confounders was performed. Each of the confounding
variables (hospital bed size, geographical location, and variables that were not included
in the “best” model, e.g. CMI, other antibiotic classes) were added to the model to
assess their impact on parameter estimates. A confounding variable that changed
parameter estimates by ≥ 20% was added to the selected model.[123] For the test of
model effects, Type III, was selected for all analysis as it does not depend on the entry
order of the variables like Type I does. Test Type III is typically preferred unless the
order of the variables is necessary.[117]
For CR-KP dependent variable, the following explanatory variables were included in the
model selection process: fluoroquinolones (ciprofloxacin, levofloxacin, gatifloxacin,
moxifloxcacin); carbapenems (imipenem, meropenem, doripenem, ertapenem);
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antipseudomonal penicillins (piperacillin-tazobactam, ticarcillin-clavulanate); third-and
fourth-generation cephalosporins (ceftazidime, cefepime, aztreonam, ceftriaxone,
cefotaxime); aminoglycosides (gentamicin, tobramycin, amikacin); hospital CMI;
patient-proportion within the APR-DRG categories; and geographical location.
After selecting the model; the adjustment for potential confounders was performed in a
similar fashion to the CR-PA modeling process.
3.10 Human subjects’ protection and data privacy

VCU IRB exemption was obtained for this study. A dataset was constructed from the
University Health System Consortium (UHC) data warehouse. Access to the dataset
was restricted to those individuals listed on the study protocol, and the dataset was
centrally maintained in a password-protected environment. Disclosure of any kind of
information did not take place without the expressed written permission of UHC or as
required by law. Results will be published in such a way that no hospital will be
individually identifiable. Data within UHC‟s Clinical Resource Manager is compliant with
the Health Insurance Portability and Accountability Act of 1996 (HIPAA). This study
qualified for exemption according to 45 CFR 46.101(b) Category 4 at Virginia 56
Commonwealth University internal review board VCU IRB#: 12377. A copy of the IRB
Approval form can be found in the Appendix B.
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CHAPTER 4
Results

4.1 Descriptive statistics of hospitals
Forty hospitals were included in the analysis of this project out of the 50 hospitals
approached. Six of the total 50 hospitals did not provide any antibiograms nor did they
respond to the survey. One hospital responded to the survey but did not provide any
antibiograms. Three hospitals provided antibiograms that cannot be used; two of them
did not include carbapenem susceptibility results and one antibiogram did not include
the total number of isolates for organisms of interest.
The 40 participating hospitals were located in different geographical locations across
the continental U.S. Eight of the participating hospitals were located in the Mid-Western
region, eight hospitals were located in the Mid-Continent region, ten hospitals were
located in the Mid-Atlantic region, both the South-Western and Western regions had six
hospitals in each, and two hospitals were located in the New-England region. Table 4.1
lists patient and hospital demographics for 2009 at 40 UHC hospitals.
The observations in the study period represent a total of 22,224,512 total patient days
and 3,960,380 discharges. During this period, 2,022,956 patients received antibiotics.
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Table 4.1 Characteristics of 40 member hospitals of the UHC in 2009
Characteristics

Mean (SD)

Range

Adult patient age

52 ± 4

44 - 59

Bed size

558 ±190

216 - 1156

Case mix index

1.67 ± 0.16

1.21 – 1.99

Mean length of stay, days

5.59 ± 0.45

4.74 – 6.79

Total Patient Discharges

25283 ± 8615

11594 - 54192

Total Patient Days

141509 ± 48733

59763 - 282327

Surgical procedures per

356 ± 56

194 - 502

1000 discharges
Diagnosis per 1000 discharges
Urinary Tract infections

86 ± 15

49 - 119

Pneumonias

62 ± 12

40 - 94

Blood stream infections

54 ± 11

31- 88

Bone marrow transplants

3.5 ± 3.2

0 - 15

Solid organ transplants

10.4 ± 6.3

0 - 29

one hospital was excluded for these characteristics
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4.2 Summary statistics of antibiotic use
Antibiotics use data were available for all 40 hospitals over the study period. Each
antimicrobial group was assessed for trends over the study period. The mean (± SD) of
antibiotics under this investigation are presented in table 4.2 and figure 4.1. One
hospital’s antibiotic use data for 2009 was excluded because the data for that year were
not correct. For antipseudomonal penicillins, piperacillin-tazobactam was mainly used in
most hospitals. Total use of five broad spectrum antibiotic classes increased
significantly over the study period, from 354.0 (± 72.2) DOT/1000 PDs in 2006, to 369.7
(± 80.3) DOT/1000 PDs in 2009 (P=.0206). This increase is driven primarily by an
increase in carbapenem and piperacillin-tazobactam use. Total carbapenem use
increased by 24% over the study period, from 36.1(± 21.7) DOT/1000 PDs in 2006, to
44.8 (±24.4) DOT/1000 PDs in 2009, (P <.0001). A similar increase of 25% was
observed with piperacillin-tazobactam use 73.8 (±39.6) DOT/1000 PDs in 2006 to 92.3
(±37.2) DOT/ 1000 PDs in 2009 (P <.0001). On the other hand, total fluoroquinolone
use decreased by 8% over the study period; from 130.0 (± 40.6) DOT/1000 PDs in
2006, to 119.6 (± 36.9) DOT/ 1000 PDs in 2009 (P= 0.0013). Total aminoglycoside use
decreased by 18% over the period of this investigation, from 28.3 (± 9.5) DOT/1000
PDs in 2006, to 23.1 (± 8.7) DOT/1000 PDs in 2009 (P<0.0001). Total third-and fourthgeneration cephalosporin use did not change significantly over the study period. It is
worth mentioning that fluoroquinolone use represented the highest proportion of broad
spectrum antibiotics. For example, in 2009 fluoroquinolone use was 32%, followed by
piperacillin-tazobactam 25%, total third-and fourth-generation cephalosporins 25%,
carbapenem use was 12%, and finally aminoglycosides use was 6% of total use.
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Table 4.2 Changes in antibacterial drug use among 5 classes of broad spectrum
antibiotics from 2006 -2009
Antibiotic

Year

Mean use

SD

Range

(DOT/1000PDs)
Carbapenems

Fluoroquinolones

Third-and fourth-generation
cephalosporins

Aminoglycosides

2006 35.92

21.71 7.00- 98.8

2007 38.96

21.78 11.32 -98.54

2008 42.19

24.8

2009 44.80

24.38 8.51 –
160.56

2006 130.01

40.55 52.93 –
212.53

2007 129.85

37.89 51.19 –
217.70

2008 124.96

39.71 44.01 –
219.31

2009 119.62

36.87 41.73 –
200.63

2006 87.44

35.50 24.97 –
226.37

2007 89.84

34.87 27.80 –
228.55

2008 89.77

33.14 26.09 –
217.43

2009 92.24

37.47 23.37 –
253.17

2006 28.33

9.53

16.25- 61.85

2007 27.49

9.04

14.85 –
58.11
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10.80 –
121.72

Antipseudomonal penicillins

2008 25.34

8.72

12.10 –
53.54

2009 23.05

8.65

10.11 –
46.17

2006 76.69

37.30 1.66 –
175.75

2007 81.83

37.53 1.91 –
155.88

2008 89.13

36.54 3.05 –
149.15

2009 93.53

38.69 3.67 –
161.31

57

Figure 4.1 Changes in antibacterial drug use and carbapenem-resistant P. aeruginosa
over 4 years
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4.3 Summary statistics of resistance
Antibiograms were available for 40 hospitals. Of the total 160 possible hospital years,
antibiograms that met the criteria (identified in methods chapter, section 3.5) were
available for 146 (91.25%). Four years of antibiograms from 30 hospitals, three years
of data from eight hospitals, and two years of data from 2 hospitals were obtained. CRPA and CR-KP rates and proportions are summarized in tables 4.3 and 4.4 respectively.
4.3.1 Carbapenem-resistant P. aeruginosa
The mean, standard deviation, and range calculated values are presented in table 4.3.
The mean proportion and incidence rate for carbapenem-resistant Pseudomonas
aeruginosa (per 1000 patient days and discharges) did not change significantly over
the study period (P = 0.30, 0.17, 0.12; respectively, figure 4.3).
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Table 4.3 Changes in carbapenem susceptibility among P. aeruginosa
Bacteria-resistance measure

Year

CR-PA proportion (%)

2006 20

6.9

7 - 37

2007 20

7.7

6 - 36

2008 19

7.7

5 - 36

2009 19

5.7

6 - 30

2006 1.02

0.65 0.10 – 2.65

2007 1.00

0.72 0.20- 2.80

2008 0.91

0.72 0.15 – 2.66

2009 0.88

0.57 0.19 – 2.12

CR-PA rate (1000 discharges) 2006 5.73

3.87 0.42– 15.02

2007 5.67

4.30 1.18 – 16.30

2008 5.31

4.61 0.83 – 18.78

2009 4.93

3.43 1.09 – 12.89

CR-PA rate (1000 PDs)

Mean SD
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Range

4.3.2 Carbapenem-resistant K. pneumoniae
The median, interquartile range and total range were calculated for each of the four
years and are presented in table 4.4. Microbiology results obtained from antibiograms
for CR-KP varied among hospitals and the years of this study. Almost one half of the
participating hospitals (22 hospitals) reported 0.5 to 2 percent carbapenem-resistant K.
pneumoniae in at least one year of the study period. Nine hospitals reported a zero
percent of CR-KP for all years, while 4 hospital hospitals reported a CR-KP percent that
is more than 2 and less than 10 in at least one year of the study period. Twenty seven
hospitals had zero percent/rate of CR-KP as reported in their antibiograms; this number
decreased over the study period as follows: 22 hospitals in 2006, 20 hospitals in 2007;
17 hospitals in 2008; and 10 hospitals in 2009. Further, five hospitals reported a CR- KP
proportion of more than 10% in at least one year of the study period. The five hospitals
with the highest proportions of CR-KP were all located in the Mid-Atlantic region of the
U.S. The total number of CR-KP isolates was calculated for all the participating
hospitals over the study period to show the increase in these isolates over time, as
shown in figure 4.2.
The mean proportion of carbapenem-resistant K. pneumoniae increased by 130%, from
a mean of 1.3% in year 2006 to a mean of 3.1% in year 2009 (P=0.003, Table 4.5,
figure 4.3) and the mean incidence rate for carbapenem-resistant K. pneumoniae (per
1000 patient days) increased by 120%, from 0.07 in year 2006 to 1.52 in 2009 (P
=0.0118, table 4.6, figure 4.3).
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Table 4.4 Changes in carbapenem-resistant K. pneumoniae over the study period
Bacteria-resistance measure

year

CR-KP proportion (%)

2006 0.0

0-1

0 – 14

2007 0.0

0-1

0 - 20

2008 1.0

0-2

0 - 20

2009 1.0

0-2

0 - 23

2006 0.0

0 - 0.05 0 - 1.054

2007 0.0

0 - 0.05 0 - 0.548

2008 0.02

0 - 0.06 0 - 1.002

2009 0.04

0 - 0.07 0 - 1.049

CR-KP rate (1000 PDs)

Median IQR

CR-KP rate (1000 discharges) 2006 0

0- 0.26

range

0 - 5.98

2007 0

0 - 0.30 0 - 3.48

2008 0.12

0 - 0.34 0 - 6.27

2009 0.21

0 - 0.40 0 – 5.78
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Figure 4.2 Total number of carbapenem-resistant K. pneumoniae isolates over the study
period
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Table 4.5 Changes in carbapenem-resistant K. pneumoniae proportions (%)
Year

LS means

SE

Lower CI 95%

Upper CI 95%

2006

1.33

0.69

-0.057

2.721

2007

1.63

0.69

0.245

3.013

2008

2.33

0.69

0.943

3.713

2009

3.08

0.72

1.644

4.519

64

Table 4.6 Changes in carbapenem-resistant K. pneumoniae rates/1000 PDs
Year

LS means

SE

Lower 95% CI

Upper 95% CI

2006

0.07

0.03

0.002

0.138

2007

0.06

0.03

-0.006

0.130

2008

0.10

0.03

0.031

0.166

2009

0.15

0.04

0.081

0.224
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Figure 4.3 Changes in carbapenem-resistant P. aeruginosa and K. pneumoniae over
the four years
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4.4 Survey
The response rate for the online survey was 64%. Among the thirty-two hospitals
responded two hospitals were excluded because one hospital did not provide any
antibiograms and the second hospital antibiograms were not including number of
isolates. For the first part of the survey (antibiogram construction), data from previous
projects were used.
4.4.1 Antibiogram construction

Antibiograms construction information was available for 38 hospitals out of the total 40
hospitals included in the study. Data about antibiogram construction from another
project were used for this study. Multiple methods were employed in year 2009 for
routine susceptibility testing, including MicroScan (n = 9), Vitek 2 (n = 11), disk diffusion
(n = 5), Phoenix (n = 9), Vitek (n=3) and Sensititre (n=1). Thirty-one hospitals reported
removing duplicate isolates from the same patient from their annual antibiograms; while
seven hospitals included duplicates (two of them included all duplicates while the other
five included some). Thirty-two hospitals reported that surveillance cultures were
excluded, and six hospitals included surveillance cultures in their annual antibiograms.
The next two sections described responses of thirty hospitals to the remaining
components of the survey.
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4.4.2 Carbapenem-resistant K. pneumoniae

The survey results of this section are summarized in table 4.7. Twenty-seven hospitals
reported that they have encountered clinical isolates of carbapenem-resistant
Enterobacteriaceae including carbapenem-resistant K. pneumoniae within the past 5
years, while three hospitals reported they had not. Of the twenty seven hospitals,
eighteen hospitals reported their CRE isolates represented both colonized and clinical
(caused clinical infection) organisms. Five hospitals reported that they were clinical
isolates only, two reported they were colonizing isolates only, and two hospitals were
not sure. The approximate rate of isolation of carbapenem-resistant Enterobacteriaceae
(all unique isolates from individual patients) varied in 2010 among hospitals. Around
50% of hospitals (14 hospitals) reported an isolation rate of < 5 patients in the past year,
seven hospitals encountered CRE in 5 - 20 patients and six hospitals reported more the
20 patients. These isolates were from patients transferred from another hospital and /or
long-term care facility in 12 hospitals. Thirteen hospitals were not sure of the source,
while just two hospitals reported that these isolates were not from transferred patients.
Microbiological tests used to identify and confirm CRE including carbapenem-resistant
K. pneumoniae varied among hospitals. Most hospitals used imipenem, meropenem, or
ertapenem (mainly imipenem) resistance on routine susceptibility test to identify the
CRE isolates and then confirmed by the following microbiological methods: Modified
Hodge test (n=14); PCR (n=3); E-test (n=1); Modified Hodge test and PCR (n=2);
Modified Hodge test, Etest, and PCR (n=1); Modified Hodge test, indirect phenotypic
test, and PCR (n=1); other (n=1). However, four hospitals did not use any confirmatory
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testing and relied on imipenem or meropenem resistance on routine susceptibility
testing.
Part of this survey was to compare if these hospital antibiograms reflected the
approximate rate of isolation of CR-KP. According to the survey, twenty hospitals
reported that their antibiograms for 2009 and/or 2010 accurately reflected the
approximate rate of isolation of CRE organisms, and they reflected the rate of isolation
even with a small percentage. They were asked in particular, “For example, if you
isolate CREs ‘only rarely’, does your antibiogram show that a small percentage of
isolates (e.g., 1 or 2%) of K. pneumoniae are resistant to imipenem or meropenem?”
Five hospitals reported that they did not include such a percentage in their
antibiograms. However, four of these hospitals reported an isolation rate of less than
five isolates in the last year which would not affect this study. Additionally, when the
rates obtained from antibiograms in 2009 and the rates obtained via the survey were
compared they were highly correlated (r = 0.85, P<0.0001).
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Table 4.7 Survey summary results: Carbapenem-resistant K. pneumoniae
Criteria

results

CR-KP encounter

27/30

Type of isolates

Colonized &

Clinical only

Colonized

clinical

(5/27)

only

(18/27)

(2/27)

Rate of isolation in

<5

5-20

>20

the past year

(14/27)

(7/27)

(6/27)

Source

Transferred

Not sure of

Not from

from another

the source

transferred

hospital /

(13/27)

patients

long-term

Unknown

(2/27)

(2/27)

care facility
(12/27)
Microbiology test

MHT (14)

PCR ( 3)

E-test (1)

MHT,PCR (2)

used to confirm

MHT, PCR,

MHT, PCR,

Other (1)

Routine

KPC

E-test (1)

indirect

susceptibility

phenotypic

only ( 4)

test (1)

ASP

Yes (24/30)

No (6/30)

ASP role in KPC

Monitor &

Don not

intervene

monitor of

(21/24)

intervene
(3/24)

Isolation

(24/24)

procedures for
infected/colonized
patients
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4.4.3 Antimicrobial stewardship efforts

Twenty-four hospitals reported having a formal ASP, while six hospitals reported not
having an antimicrobial stewardship program in their institution. Of the twenty-four
hospitals, twenty-one hospitals had their antimicrobial stewardship personnel monitor
and intervene with CRE including CR-KP infections and/or colonization cases in
accordance with infection control personnel, whereas the other three hospitals
antimicrobial stewardship personnel do not intervene in these cases. All of the hospitals
reported conducting isolation procedures for patients infected or colonized with CRE
including CR-KP and implementing strict infection control measures. Most of the CRE
cases were handled on a case-by-case basis. Finally, more than half of the responders
reported no significant changes in their antimicrobial stewardship activities/program
during the years 2006-2009. The other hospitals reported significant improvements in
the enforcement of their ASP activities.
One of the survey questions was about the restriction policy of carbapenems. A total of
19 hospitals responded that they restricted carbapenems. Of these, eleven hospitals
had restriction policies that entailed a preauthorization requirement. A preauthorization
restriction policy was one in which prior approval was required by either pharmacy or
medical personnel before the carbapenem agent was dispensed for at least some
patient populations. The other eight hospitals stated that they restricted carbapenems,
but did not require preauthorization. For example, a restriction policy may entail that a
carbapenem could be dispensed upon a physician order provided appropriate criteria
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for use were met, such as febrile neturopenia, but the restriction policy did not require
preauthorization or confirmation that the carbapenem order met the usage criteria
before the drug was released from the pharmacy.
It was not known how long the restriction policy had been implemented; thus, 2009
mean carbapenem use and CR-PA rates and proportions were compared for hospitals
that did (n = 19) vs. those that did not restrict carbapenems (n =11), as displayed in
table 4.8. Although carbapenem use was lower in hospitals that restricted
carbapenems, there were not any statistical differences in either CR-PA and CR-KP
rates or proportions for 2009.

Table 4.8 Carbapenem use (DOT/1000PDs) and resistance based on restriction status
of carbapenems in 29 hospitals in 2009

Carbapenems

Restriction

No restriction

Mean ±SD

Mean ±SD

Wilcoxon rank test p-value

34.96 ±19.53 62.05 ± 26.58 0.0111
CR-PA rate (1000 PDs) Mean ±SD

Mean ±SD

0.75 ± 0.42

0.96 ±0.75

Mean ±SD

Mean ±SD

17 ± 5

19 ± 7

CR-PA proportion (%)

one hospital data was excluded.
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0.4568

0.6523

4.5 Carbapenem-resistant P. aeruginosa rates/1000 PDs explanatory
model
A GEE model utilizing normal distribution and identity link was fitted to explain CR-PA
rates/1000 PDs. The model (with lowest QICu) to explain CR-PA rates included the
variables of fluoroquinolone use (ciprofloxacin, levofloxacin, gatifloxacin), carbapenem
use (imipenem, meropenem, doripenem), antipseudomonal penicillin use, and
antipseudomonal cephalosporin use. Most of the other proposed models had a very
similar QICᵤ score to the best model, ∆QICᵤ =1.0. The full model had a ∆QICᵤ =3.0 from
the best model. Hence, the simplest model identified above was chosen model to
explain CR-PA rates as shown in table 4.9. According to the GEE analysis, none of the
antipseudomonal antibiotics included in the model were associated significantly with
CR-PA rates/1000 PDs.
After selecting the model, adjusting for each of the potential confounders (hospital bed
size, CMI, aminoglycoside use, and hospital geographical location) was conducted. The
change in the parameter estimates were less than 1% after adding bed size, less than
10% after adding aminoglycosides, and ≥ 20% after adding, CMI, and geographical
location. Consequently, the last two confounding variables were added to the model and
the adjusted parameter estimates are displayed in table 4.10. According to the GEE
analysis, none of the antipseudomonal antibiotics included in the model were
associated significantly with CR-PA rates/1000 PDs.
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Table 4.9 GEE analysis with carbapenem-resistant P. aeruginosa rates/1000 PDs as
the dependent variable (crude estimates)
Parameter

β

SE

Z

P value

Intercept

1.015

0.257

3.94

<0.0001

Flourquinolines

0.002

0.001

1.51

0.1305

Carbapenems

-0.002

0.004

-0.52

0.6007

0.003

-0.16

0.8750

0.00

-1.55

0.1220

Antipseudomonal -0.0004
cephalosporins
Antipseudomonal -0.002
penicillins

74

Table 4.10 GEE analysis with carbapenem-resistant P. aeruginosa rates/1000 PDs as
the dependent variable (adjusted estimates).
Parameter

β

SE

Z

Intercept

-0.693

0.850

-0.81 0.4151

Carbapenems

-0.004

0.0034 -1.25 0.2093

Fluoroquinolones

0.002

0.0014 1.53

P value

0.1250

Antipseudomonal cephalosporins -0.001

0.0022 -0.28 0.7827

Antipseudomonal penicillins

-0.003

0.0018 -1.57 0.1171

CMI

1.099

0.551

1.99

0.0461

0.1004

0.356

0.28

0.7780

0.1429

0.316

0.45

0.6506

-0.1672 0.279

0.60

0.5488

-0.0503 .387

-0.13 0.8967

-0.209

-0.38 0.7063

Geographical region
(Mid-Western vs. Mid-Atlantic)
Geographical region
(Mid-Continent vs. Mid-Atlantic)
Geographical region
(Southeastern vs. Mid-Atlantic)
Geographical region
(Western vs. Mid-Atlantic)
Geographical region
0.555

(New-England vs. Mid-Atlantic)
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The steps that were performed after selecting the persimmons model were repeated,
but with the proportion of patients in each of the four APR-DRG grouper scores. The
model (with lowest QICᵤ) to explain CR-PA rates included the variables of
fluoroquinolone use (ciprofloxacin, levofloxacin, gatifloxacin), carbapenem use
(imipenem, meropenem, doripenem), antipseudomonal penicillin use, and
antipseudomonal cephalosporin use. This was followed by adjusting for potential
confounders (hospital bed size, aminoglycoside use, hospital geographical location, and
APR-DRG scores proportions). Consequently, the APR-DRG groups and geographical
location were added to the model, and the adjusted parameter estimates are displayed
in table 4.11. According to GEE analysis, there was no significant association between
CR-PA rates/ PDs and any of the variables proposed by the model.
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Table 4.11 GEE analysis with carbapenem-resistant P. aeruginosa rate/1000 PDs as
the dependent factor and APR-DRG independent variables (adjusted estimates)
Parameter

β

SE

Intercept

1.103

1.067 1.03

Z

P value
0.3015

Antipseudomonal cephalosporins -0.003 0.002 -1.39 0.1647
Carbapenems

-0.004 0.004 0.90

0.3674

Fluoroquinolones

0.002

0.2169

Antipseudomonal cephalosporins

-0.001 0.003 -0.31 0.7549

Geographical region

0.057

0.362 0.16

0.8755

0.080

0.338 0.24

0.8139

0.002 1.23

(Mid-Western vs. Mid-Atlantic)
Geographical region
(Mid-Continent vs. Mid-Atlantic)
Geographical region

-0.116 0.275 -0.42 0.6729

(Southeastern vs. Mid-Atlantic)
Geographical region

0.007

0.350 0.02

0.9837

(Western vs. Mid-Atlantic)
Geographical region

-0.183 0.524 -0.35 0.7268

(New-England vs. Mid-Atlantic)
APR-DRG proportions
(base-minor)
Extreme

2.640

Major

-0.669 2.324 -0.29 0.7736

Moderate

-0.113 2.542 -0.04 0.9645
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5.779 0.46

0.6478

4.6 Carbapenem-resistant P. aeruginosa proportion explanatory
model
A GEE model utilizing binomial distribution and logit link was fitted to explain CR-PA
proportions. The model (with lowest QICᵤ) to explain variability in CR-PA proportions
included the variables of fluoroquinolone use, carbapenem use, and antipseudomonal
cephalosporin use. The second best model had a QICᵤ score close to the best model,
∆QICᵤ 2.15, and included antipseudomonal penicllins in addition to the variables
identified in the previous model. Using the principle of parsimony, the model with the
lowest QICᵤ and fewest explanatory variables was selected. According to the GEE
analysis, none of the antipseudomonal antibiotics included in the model were
associated significantly with CR-PA proportions over the study period as displayed in
table 4.12.
Each of the potential confounding variables (case mix index, bed size, geographical
location, aminoglycoside use, and antipseudomonal penicillins) was adjusted for in a
similar fashion to the method used in section 4.5. Table 4.13 represents the parameter
estimates for the adjusted explanatory model. The parameter estimates were
exponentiated for interpretation purposes. According to the GEE analysis, none of the
antipseudomonal antibiotics included in the model were associated significantly with
CR-PA proportions over the study period.
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Table 4.12 GEE analysis with carbapenem-resistant P. aeruginosa proportions as the
dependent variable (crude estimates)
Parameter

β

Exp(β)

SE

Z

P value

Intercept

-1.508

0.221

0.172

-8.76

<0.0001

Carbapenems

0.003

1.003

0.003

0.97

0.3317

Fluoroquinolones 0.002

1.002

0.001

1.14

0.2524

Antipseudomonal -0.002

0.998

0.003

-0.42

0.6737

cephalosporins
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Table 4.13 GEE analysis with carbapenem-resistant P. aeruginosa proportion as the
dependent variable (adjusted estimates)
Parameter

β

Exp(β)

SE

Z

P value

Intercept

-2.451

0.086

0.668

-3.67

0.0002

Carbapenems

0.004

1.004

0.003

1.26

0.2076

Fluoroquinolones

0.002

1.002

0.001

1.48

0.1388

Antipseudomonal cephalosporins

-0.003

0.997

0.002

-1.29

0.1974

Antipseudomonal penicillins

-0.003

0.997

0.002

-2.02

0.0437

CMI

0.703

2.020

0.463

1.52

0.1291

Geographical region

0.342

1.408

0.211

1.62

0.1051

-0.337

0.714

0.257

-1.31

0.1900

0.295

0.745

0.223

1.16

0.2455

-0.343

0.710

0.182

-1.88

0.0596

-0.209

0.811

0.191

-1.10

0.2733

(Mid-Continent vs. Mid-Western)
Geographical region
(Southeastern vs. Mid-Western)
Geographical region
(Mid-Atlantic vs. Mid-Western)
Geographical region
(Western vs. Mid-Western)
Geographical region
(New-England vs. Mid-Western)
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4.7 Carbapenem-resistant K. pneumoniae explanatory model
A GEE model utilizing a binomial distribution and logit link was used to model CR-KP.
The best model for explaining CR-KP isolates presence in the 40 hospitals included the
variables of carbapenem use, fluoroquinolone use, aminoglycoside use,
antipseudomonal penicillins, and hospital geographical location. The second best model
had a QICᵤ score very similar to the best model, ∆QICᵤ 1.80, and included carbapenem
use, fluoroquinolone use, third-and forth-cephalosporin use, aminoglycoside use,
antipseudomonal penicillins, and geographical location. Using the principle of
parsimony, the model with lowest QICᵤ and fewest explanatory variables was preferred.
The parameter estimates were exponentiated for interpretation purposes
After selecting the "best" model, it was adjusted for the potential confounders (bed size,
CMI, third-and fourth-generation cephalosporins) similar to the method used in section
4.5. None of the confounding variables changed the parameter estimate by more than
20%; hence, the crude estimates were used. Table 4.14 represents the parameter
estimates for the explanatory model.
According to GEE analysis, carbapenem antibiotic use was significantly (P=0.0149)
associated with the presence of CR-KP isolates. Thus, the estimated change in the
odds of carbapenem-resistant K. pneumoniae for a one-unit increase in carbapenem
antibiotic use is 1.04 with a 95% confidence interval of (1.02, 1.06). This means that for
ten DOT/1000 PDs increase in carbapenem use, the odds of carbapenem-resistant K.
pneumoniae isolation increase by 42%. Hospitals located in the Midwestern,
Midcontinent, Western, and New -England regions of the nation were less likely to
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encounter CR-KP isolates when compared to hospitals located in the Mid-Atlantic
region of the nation (P = 0.0002, 0.0140, 0.0001, 0.0304, respectively).
Finally, antipseudomonal penicillin use was significantly associated with CR-KP
isolation (P=0.0477). Thus, the estimated change in the odds of carbapenem-resistant
K. pneumoniae for a one unit increase in antipseudomonal penicillin antibiotic use is
0.985 with 95% confidence interval of (-0.0298,-0.0002). This means that for a ten DOT/
1000 PDs increase in antipseudomonal penicillin use, the odds of CR-KP isolation
decreased by 14%.
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Table 4.14 GEE analysis with carbapenem-resistant K. pneumoniae as the dependent
variable
Parameters

β

Exp(β)

Intercept

4.002

54.407 1.477 2.71

0.0067

Carbapenems

0.035

1.036

0.014 2.43

0.0149

Fluoroquinolones

-0.009 0.991

0.006 -1.63

0.1033

Antipseudomonal Penicillins

-0.015 0.985

0.008 -1.98

0.0477

Aminoglycosides

-0.053 0.948

0.027 -1.93

0.0537

Geographical region

-2.922 0.054

0.779 -3.75

0.0002

-2.688 0.068

1.049 -2.56

0.0140

-0.781 0.458

0.968 -0.81

0.4199

-4.399 0.012

1.138 -3.86

0.0001

-3.057 0.047

1.413 -2.16

0.0304

SE

Z score P value

(Mid-Western vs. Mid-Atlantic)
Geographical region
(Mid-Continent vs. Mid-Atlantic)
Geographical region
(Southeastern vs. Mid-Atlantic)
Geographical region
(Western vs. Mid-Atlantic)
Geographical region
(New-England vs. Mid-Atlantic)

*bolded = P value < 0.05
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CHAPTER 5
Discussion

5.1 Summary of findings
This chapter summarizes the study, providing a discussion of the study results,
conclusions, limitations, and suggestions for future research.
In this current investigation, it was attempted to explain carbapenem-resistant
Pseudomonas aeruginosa and Klebsiella pneumoniae in a consortium of academic
medical centers over the period from 2006-2009.
Objective 1 described trends of antimicrobial use in 40 hospitals over the study period.
Total broad spectrum antibiotics for five classes of gram-negative antibiotics increased
over time. Carbapenem and piperacillin-tazobactam use increased by 25%, while
fluoroquinolone and aminoglycoside use decreased over time.
Objective 2 described rates and proportions of CR-PA and showed rates and
proportions of CR-PA to be stable over four years.
Objective 3 described rates, proportions, and number of CR-KP and showed an
increase of CR-KP over the four-year period. Moreover, the CR-KP isolation rate,
isolation procedure, source, microbiological identification techniques, and isolation rate
were described in thirty hospitals via a survey. CR-KP rates obtained from antibiograms
were strongly correlated with rates obtained by the survey. Hospitals conducted strict
measures with regard to isolation of such organisms.
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Objective 4 identified important predictors of CR-KP isolation within the 40 participating
hospitals over four-year period among broad spectrum gram-negative antibiotic classes,
CMI, and hospital demographics (bed size, geographical location). The GEE analysis
utilizing binary distribution and logit link showed a significant association between
hospital geographical location and carbapenem use, and antipseudomonal penicillin
use. However, no significant predictors were associated with CR-PA rates/1000 PDs or
proportions over the study period.

5.2 Discussion of results by objective

Objective 1
Descriptive statistics were used to assess current broad spectrum gram-negative
antibiotic use in U.S. academic medical centers. The observations of this investigation
are updated and consistent with prior investigation of antibiotic use in UHC consortium
of hospitals from 2002 to 2006 conducted by Pakyz et al.[48] The previous investigation
showed a 59% increase in carbapenem use and an 84% increase in the use of
piperacillin-tazobactam between 2002 and 2006. However, this investigation showed a
lower rate of increase in carbapenem use and piperacillin-tazobactam over the period of
2006 to 2009, 24% and 25% respectively. Further exploration assessed 19 hospitals
that restricted carbapenem use and found they used less carbapenems than hospitals
that did not restrict carbapenems, but had a significant (P=.0001) increase in
carbapenem use, from 29.31 DOT/1000 PDs in 2006 to 39.80 DOT/1000 PDs in 2009.
Carbapenem use increased presumably because of increasing resistance among gram85

negative organisms, including ESBLs producing Enterobacteriaceae, to other more
commonly used antimicrobial agents.[124, 125] The proportion of piperacillintazobactam use was similar to the proportion of total third-and fourth-generation
cephalosporin use. Fluoroquinolone use decreased slightly over the study period;
however, they remained the most commonly prescribed class of antibiotics among
broad spectrum antimicrobials throughout the study period. The previous investigation
showed stability in fluoroquinolone use over 2002 -2006; however, this investigation
includes twice as many hospitals. Similar to Pakyz et al., third- and fourth-generation
cephalosporin use did not change during the study period. Finally, aminoglycoside use
was decreasing in the current study sample.

Objective 2
In the current investigation, rates and proportions of CR-PA remained stable or even
declined over four years, while the mean use of carbapenems increased. This
observation is supported by similar recent investigation of CR-PA proportion over six
years in 25 hospitals.[47] CR-PA resistance is stable over time, although carbapenem
use is increasing over the same period. However, most of these organisms are
multidrug resistant, and the contributions of other antibacterial compounds to their
prevalence remains to be fully explained.[50] In the same context, when hospitals
which restricted the availability of carbapenem antibiotics were compared to those
which did not restrict, it was found that hospitals restricted carbapenem used
significantly less than hospitals that did not restrict use, but restriction was not
associated with lower rates of CR-PA.
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Objective 3
The rates and proportions of CR-KP varied among the participating hospitals in this
investigation. Proportions and rates of CR-KP increased by 120% and 130%,
respectively, between 2006 and 2009. However, the magnitude of this increase varied
considerably among hospitals, as some hospitals reported outbreaks (more than100
isolate per year), while some hospitals reported the isolation of less than 5 isolates.
However, this observation is not consistent with the MYSTIC report that found the
incidence of KPC to be declined in 2008 compared to the steep increase in resistance
rates observed from 2004 to 2007 [71]. This is likely due to the larger number of
participating hospitals of this investigation compared to the MYSTIC report (40 vs. 15).
Furthermore, the CDC reported, as of December 2010, that KPC-producing isolates
have been received or identified from 36 states, which indicates the spread of these
organisms. [28,36] Carbapenem-resistant K. pneumoniae is the most common
carbapenem-resistant Enterobacteriaceae in the United States. Based on the survey
results for 30 hospitals, antibiograms were found to reflect the approximate rate of
isolation of CR-KP, specifically, both rates from antibiograms and the survey were
highly correlated for 2009. Almost one half of the responders confirmed the isolation of
CRE to be of transferred patients from another hospital and/or long-term care facility
which is the true case in most outbreaks reported as patients come to the hospital from
another healthcare facility carrying these organisms. However, the other half of the
responders were not sure about the source of CRE isolates; these could be from
hospital patients. The presence of CR-KP carriage has been described in a number of
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studies involving patients from long-term acute care hospitals.[126-128] One
investigation found that more than half of the patients with carbapenem-resistant gramnegative bacteria were admitted from post-acute care facilities implying that these
health-care settings may be significant reservoirs for transmission and spread of these
bacteria. [127] According to the survey results, most of the hospital’s CRE isolates
were both colonizing and clinical isolates which can occur with the presence of a small
number of CR-KP clinical cases. For example, one investigation of three patients with
CR-KP infection transferred from long-term acute care hospital showed that 49% of the
residents were having colonized with CRE isolates.[27] The majority of the hospitals
used phenotypic method along with the imipenem (in some hospitals meropenem or
ertapenem) resistance routine susceptibility test to confirm CR-KP. Modified Hodge test
was the most common confirmatory technique used either alone, or in combination with
other techniques, mainly PCR method. Although the CLSI recommendation to change
(lower) carbapenem breakpoints were corrected in 2010, it appears that hospitals’
microbiology laboratories continue to depend on the older breakpoints in addition to
phenotypic confirmatory tests (e.g. MHT). This is likely due to the delay in the Food and
Drug Administration (FDA) approval process, consequently the automated system
manufacturers have not been able been able to provide microbiology laboratories with
validated equipments with the new CLSI breakpoints.[129] However, with the lowering
of the carbapenem breakpoints and exclusion of the need to perform MHT testing, it
remains questionable whether some patients colonized/infected with carbapenemaseproducing organisms might be missed. [129]
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One item that all hospitals were consistent about is the requirement for universal
precautions and infection control measures including patient isolation being performed
as early as colonized or infected patients with CRE were identified. Strict infection
control measures have been shown to decrease and contain the spread and the
incidence of CRE in many outbreaks. [88-90]
Objective 4
Carbapenem-resistant K. pneumoniae
The determinants of bacterial resistance are complex and multifactorial; no single
comprehensive model explaining resistance has yet been developed. This investigation
used generalized estimating equations (GEE) with binary distribution and logit link to
examine the relationship between some potential predictor variables, in particular
aggregated antimicrobial drug use, SOI (CMI), hospital demographics, and aggregated
carbapenem-resistance in clinical isolates of K. pneumoniae in a consortium of UHC
university teaching hospitals. CR-KP is resistant to most available antibiotic drugs,
leaving few options such as colistin or tigecycline, which are more toxic and possibly
less effective. [21, 26, 76] Infections with CR-KP are associated with poor outcomes
and a high mortality rate.[22,28,29] The results of this investigation showed that
carbapenem antibiotic use, geographical location, and antipseudomonal penicillins were
significantly associated with CR-KP isolation, with carbapenem use being positively
associated with CR-KP isolation. While there was no ecological study at the hospital
level to compare the findings with, this observation was in general agreement with other
single center case control studies in which prior carbapenem use was identified as an
independent risk factor for the isolation of CR-KP.[22, 29, 42, 43, 44] This investigation
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observed a significant increase in CR-KP rates and proportions over the period of 2006
to 2009 in a relatively large sample of US hospitals. Carbapenem use continued to
increase in the same set of hospitals over the study period. This increase is likely due to
the wide use of carbapenems for the treatment of severe infections caused by ESBL
producing Enterobacteriaceae including K. pneumoniae as carbapenems considered
the drug of choice in these infections. Carbapenems have been broadly used to treat
Enterobacteriaceae species which may increase antibiotic selection pressure,
consequently promoting carbapenem-resistance bacteria development.[51-53] The
specific mechanisms of CR-KP include production of KPC, metallo-beta-lactamases and
loss of porins as described in detail in chapter 2, section 2.5. This investigation included
all CR-KP isolates, regardless of the mechanism of resistance as this information could
not be obtained. Therefore, the variation in resistance mechanisms, which may be
associated with different risk factors among the CR-KP isolates, could not be
incorporated in the model to better clarify the role of carbapenem use in the isolation of
CR-KP. Additionally, hospital geographical location was identified as an independent
predictor of the CR-KP isolation. Hospitals located in the Mid-Atlantic region were more
likely to encounter CR-KP isolation when compared to hospitals located in the
Midwestern, Mid-Continent, Western, and New-England regions of the continental U.S.
The first KPC producing isolate was identified in North Carolina in 2001. Reports soon
followed from other regions of the U.S., mostly on the East Coast. Subsequently, the
escalating prevalence of CR-KP infection in the Mid-Atlantic costal region of the United
States was documented and some of these sporadic outbreaks have turned into an
endemic spread.[30-32] The CDC reported as of December 2010, that KPC-producing
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isolates have been received or identified from 36 states.[36] Hospitals located in the
Southeastern region were not different from the Mid-Atlantic region indicating the
endemic spread of these isolates in this region.
The antipseudomonal penicillins and CR-KP association was in a negative direction,
implying a favorable effect of the increase in the use of antipseudomonal penicillins
(mainly piperacillin-tazobactam) on CR-KP. The favorable impact of agents like
piperacillin-tazobactam on CR-KP could imply that hospitals using more piperacillintazobactam could be using less of other classes of antibiotics with known effect on CRKP. CMI and APR-DRG categories were not part of the final model to explain CR-KP
isolation, but adjusting for each of them was considered. However, when they were
forced into the model, there was no significant association with CR-KP isolation.
Carbapenem-resistant P.aeruginosa
This investigation used generalized estimating equations (GEE) to examine the
relationship between some potential predictor variables, in particular aggregated broad
spectrum antipseudomonal antimicrobial drug use, SOI (CMI, APR-DRG), hospital
demographics and aggregated carbapenem-resistance P. aeruginosa in a consortium of
UHC university teaching hospitals. Binomial distribution and logit link were used to
model carbapenem-resistant P. aeruginosa proportions; normal distribution and identity
link were used to model carbapenem-resistant P. aeruginosa rates/1000 PDs. The
results of this investigation showed no significant association between CR-PA
rates/1000 PDs, proportions, and any of the predictors identified in each model.
Previous single center case control studies identified prior carbapenem use,
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fluoroquinolone use, and extended-spectrum cephalosporins as risk factors for CR-PA;
however, none of the other antipseudomonal antibiotic classes identified in the model
selection process were significantly associated with CR-PA proportions and rates.
Similarly, Eagye et al. found no significant association between carbapenem use,
fluoroquinolone use, and CR-PA incidence rates in a multivariable model in 25
hospitals. [47]
Finally, when CMI was forced into the model as a predictor, there was a positive
association with CR-PA rates/1000 PDs. Hospitals with an elevated CMI have sicker
patients and perform more complicated procedure. Also, none of the APR-DRG
categories were associated with CR-PA rates or proportions when forced into the
model.

5.2 Limitations
First, the current study design is a longitudinal ecological study. Using an ecological
approach has some limitations. By definition, ecologic data contain only marginal
observations on the common distribution of individually defined confounders and
outcomes.[130] “Ecological fallacy” occurs when the results of an ecological study are
interpreted as being applied to individuals.[131] In this current investigation, the role of
aggregated antibiotic use on carbapenem-resistant gram-negative bacteria in U.S.
academic hospitals was assessed; the resulting findings do not necessarily reflect to the
patient level. Ecological (hospital-level) variables weaken the linkage between patientlevel variables including outcome, exposure, and covariates, and may result in a
complex misrepresentation at the patient-level. For example, if this same project was
conducted with patient-level data, stronger linkages would be found compared to
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ecological study results.[91] According to Harbarth et al., ecological studies in general
can identify trends, but lack sufficient details to make the case for causality between
antibiotic exposure and resistance in gram-negative bacteria. He suggested including
patient-level data analysis in these studies to provide more valid results.[131] In
contrast, Turnidge et al. stated that “given the complexity of resistance
ecology…….when correlations are shown they are almost certainly of major importance
and suggest that reduction in consumption of the correlated antibiotic class will reduce
resistance”.[132] Despite the limitations of ecological studies there was adjustments for
some confounders.
Second, the response rate for the survey or antibiogram requests was not 100%. It is
possible that those that did not respond to the survey would have different patterns of
antibacterial drug use and/or carbapenem-resistance. However, the non-responding
hospitals had similar demographic characteristics to responding hospitals; the mean
bed size, CMI, and patient age were similar among responders and non-responders.
The non-respondent rate can be explained, in part, due to changes in the infectious
diseases clinical pharmacists or physicians positions over the study period. A contact
from previous studies is more likely to respond compared to a new clinical pharmacist,
who may not be aware of the UHC CRM database.

Third, this investigation used aggregated data at the hospital-level including aggregated
susceptibility data obtained from whole-house annual antibiograms. The literature is
conflicting as to whether antibiograms are truly reflective of nosocomial resistance
rates.[133,134] However, a network of hospitals such as described in this investigation
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may be able to link changes in antimicrobial drug use to changes in resistance using
whole-house antibiograms because of greater statistical power and the potential to
adjust for confounders and some methodological differences in antibiogram reporting
methods. This interpretation is supported by the findings from a MYSTIC surveillance
project. [135] In 10 -15 medical centers observed over a 3 year period, significant
positive relationships in aggregated mean drug use and antimicrobial resistance rates
were observed for a number of “drug-bug” pairs. However, at the institution level no
significant relationships were observed. Although additional research is necessary to
determine if this approach is valid, this investigation and the limited available data
suggest that results from annual antibiograms correlate well to more established
surveillance programs. [134,136]
Additionally, there was variability between hospitals with respect to the method of
measuring susceptibility to carbapenem antibiotics. While most hospitals used CLSI
breakpoints to determine susceptibility, the source of clinical isolates between hospitals
was likely to be variable depending upon, for example, the number of specimens
obtained from outpatients and the proportion of cultures obtained from pediatric
patients. Additionally, while most hospitals did not include surveillance cultures in the
antibiogram and most deleted duplicate cultures from the same patients, this was not
always the case. Within a hospital, these sources of variability may be acceptable since
the practice is likely to be consistent, but these differences limit the ability to compare
across hospitals. However, the incorporation of some antibiogram construction data
(e.g. removal of duplicates, surveillance cultures) as covariates did not change the
results of this investigation.
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Fourth, hospital infection control measures and the impact of patient-to-patient
transmission were not measured. Patients infected with MDR bacteria from another
hospital may impact the resistance rate in that hospital.[126-128]
Finally, this study used hospital data from the UHC. Secondary databases can be
convenient since the researcher does not have to wait for the data to be prospectively
collected. However, problems with inadequate or inaccurate codes in databases may
introduce bias in the results.[137,138] While potential predictors were considered, there
may be other factors that influence the prediction of carbapenem-resistant bacteria that
were not available. Factors such as non-formulary antibiotic drug use, antimicrobial
combination therapy, and infection control measures cannot be assessed, as the UHC
database does not capture such information. Hence, these factors which contribute to
drug use and bacterial resistance were not included in the study. Further, the UHC
consists of all-payer hospital discharge data from most of the United Sates academic
medical centers. However, community hospitals are not represented.

5.4 Future research
This study provides the basis for some potential future research. While, many of these
findings were in agreement with other studies identified, some of the findings were not.
The modifiable risk factors identified in this investigation could be a potential target of
intervention by antimicrobial stewardship programs. Further, future studies that adopt a
multilevel approach would provide a better understanding between antibiotic use and
bacterial resistance. A multilevel approach takes into consideration the nested
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hierarchies of data and allows integration of observations on all available levels:
physiological (which examines exposures and responses of systems within individuals);
individual (which examines exposures and responses of individuals); and aggregate or
contextual (which examines exposures and responses of aggregates or clusters of
individuals, such as hospitals).[130,139] Incorporation of patient-level data, including
microbiology data, would potentially provide a better explanation of resistance.[131]

5.5 Conclusions
The results of this investigation did not show significant relationships between
antipseudomonal antibacterial drug use and rates or proportions of carbapenemresistant clinical isolates of P. aeruginosa in 40 UHC academic medical centers over a
four-year period. However, continued examination of these relationships will remain
important since both antibacterial drug use and resistance among many clinical isolates
will continue to evolve over time, although the direction is unclear and the
interrelationships are currently uncertain. The increasing spread of carbapenemresistant K. pneumoniae over time and across different regions of the U.S., and the
significant relationship between carbapenem antibiotics use and carbapenem-resistant
K. pneumoniae, emphasize the challenges associated with the treatment of multidruggram-negative bacteria.
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